Converted by EDGARwiz

0001511164-16-001136.txt : 20161114 0001511164-16-001136.hdr.sgml : 20161111 20161114171711 ACCESSION NUMBER: 0001511164-16-001136 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161114 DATE AS OF CHANGE: 20161114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viatar CTC Solutions Inc. CENTRAL INDEX KEY: 0001616495 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 261581305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-199619 FILM NUMBER: 161995924 BUSINESS ADDRESS: STREET 1: 116 JOHN STREET, STREET 2: SUITE 10 CITY: LOWELL STATE: MA ZIP: 01582 BUSINESS PHONE: (617) 299-6590 MAIL ADDRESS: STREET 1: 116 JOHN STREET, STREET 2: SUITE 10 CITY: LOWELL STATE: MA ZIP: 01582 10-Q 1 vrttform10q93016v4.htm FORM 10-Q Converted by EDGARwiz

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)




[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016




[ ]	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ______________ to _____________

Commission file number: 333-199619

VIATAR CTC SOLUTIONS INC.

(Exact name of Company as specified in its charter)


Delaware		26-1581305
(State or other jurisdiction of incorporation or		(I.R.S. Employer Identification No.)
organization)


116 John Street, Suite 10, Lowell, Massachusetts		01852
(Address of principal executive offices)		(Zip Code)


	(617) 299-6590
	(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [ ] No [X]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	[ ]	Accelerated filer	[ ]

Non-accelerated filer	[ ]	Smaller reporting company	[X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

As of November 14, 2016, there were 19,495,426 shares of $0.001 par value common stock issued and outstanding.

VIATAR CTC SOLUTIONS INC.

FORM 10-Q

INDEX




		Page

PART I.	Financial Information

	Item 1. Financial Statements (Unaudited).	F-1

	Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	4

	Item 3. Quantitative and Qualitative Disclosures About Market Risk.	14

	Item 4. Controls and Procedures.	15

PART II.	Other Information

	Item 1. Legal Proceedings.	16

	Item 1A. Risk Factors.	16

	Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.	16

	Item 3. Defaults Upon Senior Securities.	16

	Item 4. Mine Safety Disclosures.	16

	Item 5. Other Information.	16

	Item 6. Exhibits.	17

	Signatures	18

PART I –FINANCIAL INFORMATION

Item 1. Financial Statements

INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


	Page

Condensed Consolidated Balance Sheets as of September 30, 2016 (unaudited) and December 31 2015	F-1
Condensed Consolidated Statements of Operations for the nine and three months ended September 30, 2016 and 2015 (unaudited)	F-2
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the period ended September 30, 2016 (unaudited)	F-3
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015 (unaudited)	F-4
Notes to Condensed Consolidated Financial Statements (unaudited)	F-5

Viatar CTC Solutions Inc. and Subsidiary

Condensed Consolidated Balance Sheets


				September 30, 2016	December 31, 2015
				(Unaudited)
ASSETS

CURRENT ASSETS
	Cash			$ 630,260	$ 508,445
	Prepaid expenses			19,679	247,659
		Total current assets		649,939	756,104

	Property and equipment, net			685,264	172,793

	Investment in non-publicly traded company			-	480,000

			TOTAL ASSETS	$ 1,335,203	$ 1,408,897

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES
	Accounts payable and accrued expenses			$ 385,548	$ 368,116
	Accrued income tax liability			626,887	626,887
	Convertible notes payable - net of long term			100,000	-
		Total current liabilities		1,112,435	995,003

	Convertible notes payable, net			2,070,481	2,126,218

			TOTAL LIABILITIES	3,182,916	3,121,221

	Commitments and contingencies

STOCKHOLDERS' EQUITY (DEFICIT)
	Series A preferred stock, $.001 par value, 4,000,000 shares
		authorized, 4,000,000 shares issued and outstanding at
		September 30, 2016 and December 31, 2015, respectively		4,000	4,000
	Series B preferred stock, $.001 par value, 5,000,000 shares
		authorized, 1,733,801 and 0 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively		1,734	-
	Preferred stock, $.001 par value, 11,000,000 shares
		authorized, 0 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively		-	-
	Common stock, $.001 par value, 100,000,000 shares authorized,
		19,495,426 and 18,605,426 shares issued and outstanding at
		September 30, 2016 and December 31, 2015, respectively		19,496	18,606
	Additional paid-in capital			26,959,694	20,492,974
	Accumulated deficit			(28,822,215)	(22,217,527)
			Total stockholders' equity (deficit)	(1,837,291)	(1,701,947)

	Noncontrolling interest			(10,422)	(10,377)

			TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	(1,847,713)	(1,712,324)

			TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 1,335,203	$ 1,408,897

See notes to condensed consolidated financial statements.

F-1


Viatar CTC Solutions Inc. and Subsidiary
Condensed Consolidated Statements of Operations
(Unaudited)


			For the Nine Months Ended September 30,		For the Three Months Ended September 30,
			2016	2015	2016	2015
REVENUE
	Sales		$ -	$ 37,940	$ -	$ 13,985

COST OF REVENUE
	Cost of sales		-	7,660	-	3,830

GROSS MARGIN			-	30,280	-	10,155

EXPENSES
	Research and development		3,556,577	1,889,156	921,577	677,878
	General and administrative		2,636,588	941,534	419,932	244,066

TOTAL EXPENSES			6,193,165	2,830,690	1,341,509	921,944

LOSS FROM OPERATIONS			(6,193,165)	(2,830,690)	(1,341,509)	(921,944)

OTHER INCOME (EXPENSE)
	Dividend income		3,227	-	-	-
	Interest expense		(168,994)	(73,132)	(52,261)	(16,413)

TOTAL OTHER INCOME (EXPENSE)			(165,767)	(73,132)	(52,261)	(16,413)

LOSS BEFORE INCOME TAX EXPENSE			(6,358,932)	(2,873,542)	(1,393,770)	(928,202)

	Income tax expense		(6,750)	(6,582)	(5,799)	(6,582)

NET LOSS			(6,365,682)	(2,880,124)	(1,399,569)	(934,784)

	Net loss attributable to noncontrolling
	interest in consolidated subsidiary		(45)	(393)	(11)	(120)

NET LOSS ATTRIBUTABLE TO
	STOCKHOLDERS BEFORE PREFERRED DIVIDENDS		$ (6,365,637)	$ (2,879,731)	$ (1,399,558)	$ (934,664)

LESS: PREFERRED DIVIDENDS			(239,051)	-	(103,790)	-

NET LOSS ATTRIBUTABLE TO
	STOCKHOLDERS		$ (6,604,688)	$ (2,879,731)	$ (1,503,348)	$ (934,664)

LOSS PER COMMON SHARE - BASIC AND DILUTED:
		Net Loss Attributable to Common
		Stockholders	$ (0.34)	$ (0.16)	$ (0.08)	$ (0.05)
		Weighted Average Shares	19,196,594	17,604,366	19,495,426	17,981,054

See notes to condensed consolidated financial statements.

F-2


Viatar CTC Solutions Inc. and Subsidiary

Consolidated Statement of Stockholders' Equity (Deficit)
For the Period Ended September 30, 2016
(Unaudited)


	Series A Preferred Stock		Series B Preferred Stock		Common Stock
	Shares	Amount	Shares	Amount	Shares	Amount	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity (Deficit)	Noncontrolling Interest	Total Equity (Deficit)

Balance, December 31, 2015	4,000,000	4,000	-	-	18,605,426	18,606	20,492,974	(22,217,527)	(1,701,947)	(10,377)	(1,712,324)
Issuance of Series B Preferred stock, net of offering costs	-	-	1,679,696	1,680	-	-	4,197,560	-	4,199,240	-	4,199,240
Issuance of stock and warrants for services	-	-	-	-	890,000	890	2,133,953	-	2,134,843	-	2,134,843
Series B Preferred dividend shares	-	-	54,105	54	-	-	135,207	-	135,261	-	135,261
Series B Preferred dividend	-	-	-	-	-	-	-	(239,051)	(239,051)	-	(239,051)
Net loss	-	-	-	-	-	-	-	(6,365,637)	(6,365,637)	(45)	(6,365,682)
Balance, September 30, 2016	4,000,000	4,000	1,733,801	1,734	19,495,426	19,496	26,959,694	(28,822,215)	(1,837,291)	(10,422)	(1,847,713)

See notes to condensed consolidated financial statements.

F-3

Viatar CTC Solutions Inc. and Subsidiary

Condensed Consolidated Statements of Cash Flows

(Unaudited)


				For the Nine Months Ended September 30,
				2016	2015
CASH FLOWS FROM OPERATING ACTIVITIES:
	Net loss			$ (6,365,682)	$ (2,880,124)
	Adjustments to reconcile net loss to net cash used in
	operating activities:
		Stock based compensation		2,362,823	1,117,015
		Amortization of discount on debt		44,263	37,654
		Depreciation expense		87,368	-
	Changes in operating assets and liabilities:
		Accrued expenses		(86,358)	(69,528)

			Net cash used in operating activities	(3,957,586)	(1,794,983)

CASH FLOWS FROM INVESTING ACTIVITIES:
	Proceeds from sale of investment in non-publicly traded company			480,000	-
	Purchase of equipment			(599,839)	-

			Net cash used in investing activities	(119,839)	-

CASH FLOWS FROM FINANCING ACTIVITIES:
	Proceeds from demand note			-	50,000
	Repayment of demand notes			-	(100,000)
	Proceeds from convertible note payable			-	300,000
	Proceeds from promissory note for common stock subscription			-	611,939
	Proceeds from issuance of stock and warrants			-	1,009,125
	Proceeds from issuance of Preferred B shares, net of offering costs			4,199,240	-

			Net cash provided by financing activities	4,199,240	1,871,064

Net increase in cash and cash equivalents				121,815	76,081

Cash - beginning of the period				508,445	31,351

Cash - end of the period				$ 630,260	$ 107,432

Supplemental disclosure of cash flow information:
	Cash paid for interest			$ 54,734	$ 4,291

Supplemental disclosure of non-cash financing activities:
	Discount on debt issued with warrants			$ -	$ 31,149
	Dividends paid with Series B Preferred shares			$ 135,261	$ -
	Dividends accrued on Series B Preferred			$ 103,790	$ -

See notes to condensed consolidated financial statements.

F-4

Viatar CTC Solutions Inc. and Subsidiary

Notes to the Condensed Consolidated Financial Statements

September 30, 2016

(Unaudited)

NATURE OF OPERATIONS

Viatar CTC Solutions Inc., formerly known as Vizio Medical Devices LLC (“Vizio”), and Subsidiary (as defined below) is a pre-clinical stage company focused on medical devices for oncology applications which remove circulating tumor cells for diagnostic and therapeutic purposes.

Vizio was a Delaware limited liability company with perpetual duration that was formed on December 18, 2007. On February 25, 2014, Vizio converted to a Delaware C corporation and changed its name to Viatar CTC Solutions Inc. (“Viatar CTC Solutions”).

Viatar CTC Solutions conducts all of its operations through its subsidiary, Viatar LLC (the “Subsidiary”). The Subsidiary was formed on September 23, 2010 as a Delaware limited liability company with perpetual duration.

Viatar CTC Solutions and Vizio are together referred to as the “Company”.

Since inception, the Company has not generated significant revenues. As a result, we have incurred significant net losses and significant negative cash flows from operations.

As reflected in the accompanying condensed consolidated financial statements, the Company incurred a net loss and net cash used in operations of $6,365,682 and $3,957,586, respectively, for the nine months ended September 30, 2016. As of September 30, 2016 the Company had a working capital deficit of $462,496 and an accumulated deficit of $28,822,215. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s continued existence is dependent upon several factors, including (a) obtaining funding, whether in the form of equity, or debt investments, licensing revenues, strategic collaboration payments or grants from government or other sources, (b) success in achieving its research and development goals, (c) obtaining regulatory approvals, and (d) gaining market acceptance and/or distribution or strategic partners for its products. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company has raised approximately $21.7 million of capital since its inception, including $20.3 million from the sale of common and Series B Preferred stock, $1.4 million from convertible notes and $100,000 of demand notes. Management is continually pursuing additional funding sources.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The accompanying unaudited condensed consolidated financial statements have been prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (“GAAP”).

F-5

The financial statements contained herein have been prepared by the Company in accordance with GAAP for interim financial information. Accordingly, they do not include all information and footnotes required by GAAP for complete financial statements. The balance sheet at December 31, 2015 was derived from audited financial statements but does not include all disclosures required by GAAP. In the opinion of management, the interim financial statements include all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of the results of the periods presented. The results of operations for the nine and three months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto for the year ended December 31, 2015.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of Viatar CTC Solutions Inc., the Subsidiary and amounts related to a noncontrolling interest in the Subsidiary. The noncontrolling interest represents a 0.001% ownership interest in the Subsidiary at September 30, 2016 and December 31, 2015. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Significant estimates subject to such estimates and assumptions include the valuation of debt and equity instruments issued for services and in connection with agreements and contracts entered in to by the Company. Actual results could differ from those estimates.

Cash

The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents. The Company held no cash equivalents at September 30, 2016 or December 31, 2015.

The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash, accounts payable and accrued expenses. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of September 30, 2016 and December 31, 2015, the carrying amount of cash, accounts payable and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.

Property and Equipment

Property and equipment are recorded at cost. Depreciation expense is computed using straight-line methods over the estimated useful lives.

F-6

Asset lives for financial statement reporting of depreciation are:


Machinery and equipment		5 years

Cost-Method Investment

The Company’s cost-method investment in a non-publicly traded company is included in the condensed consolidated balance sheets and is carried at cost, adjusted for any impairment, because the Company does not have a controlling interest and does not have the ability to exercise significant influence over this company. The Company monitors any such investment for impairment on a quarterly basis, and adjusts carrying value for any impairment charges recognized. Realized gains and losses on this investment are reported in other income (expense), net in the condensed consolidated statements of operations.

As of September 30, 2016 the Company does not have any investment in any non-publicly traded company. See Note 4.

Revenue Recognition

The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the product is delivered, (3) the sales price to the customer is fixed or determinable, and (4) collectability of the related customer receivable is reasonably assured. There is no stated right of return for products. The Company generally meets these criteria upon shipment.

Cost of Sales

Cost of sales represents costs directly related to the production and manufacturing of the Company’s products for commercial sale to customers. Costs include product cost, freight, packaging, and labor costs.

Research and Development

Research and development costs consist of ongoing testing (including pre-clinical and clinical), research and development, and are expensed as incurred.

Derivatives

The Company evaluated its options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassed to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liability at the fair value of the instrument on the reclassification date.

F-7

Income Taxes

In the ordinary course of business, there is inherent uncertainty in quantifying income tax positions. The Company assesses its income tax positions and records tax assets or liabilities for all years subject to examination based upon management’s evaluation of the facts and circumstances and information available at the reporting dates. For those tax positions where it is more-likely-than-not that a tax benefit will be sustained, we have recorded the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more-likely-than-not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. The Company records interest and penalties related to uncertain tax positions as a component of income tax expense or benefit.

The Company files income tax returns with the U.S. federal government and various state and local jurisdictions. The Company is no longer subject to tax examinations by tax authorities for years prior to 2012.

The Company is currently under audit by New York City tax authorities for the 2011, 2012, and 2013 tax years. The Company applied for New York City biotechnology tax credits and received certificates of eligibility from the NYC Department of Finance in the amounts of $147,997, $242,016, and $236,874 for tax years 2013, 2012, and 2011, respectively. The Company received refunds for these amounts in previous years. The City of New York subsequently ruled that the Company does not qualify for the tax credits. As of September 30, 2016, the Company accrued $626,887 on the condensed consolidated balance sheets, as well as $194,955 of interest at the statutory rate, which is included in accounts payable and accrued expenses on the condensed consolidated balance sheets. The Company appealed the decision made by the City of New York. While settlement discussions have been held, as of the date of this report no decision has been made regarding the appeal or settlement.

Commitments and Contingencies

The Company follows subtopic 450-20 of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) to report accounting for contingencies. Certain conditions may exist as of the date the condensed consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s condensed consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

F-8

Stock-Based Compensation

In December 2004, the FASB issued ASC 718, Compensation – Stock Compensation, or ASC 718. Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. The Company amortizes such compensation amounts, if any, over the respective vesting periods of the award. The Company uses the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, that requires the input of highly complex and subjective variables, including the expected life of the award and the expected stock price volatility over a period equal to or greater than the expected life of the award.

Equity instruments (“Instruments”) issued to anyone other than employees are recorded on the basis of the fair value of the Instruments, as required by ASC 718. ASC 505, Equity Based Payments to Non-Employees, or ASC 505, defines the measurement date and recognition period for such Instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the Instruments are vested. The measured value related to the Instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.

The Company recognizes the compensation expense for all share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. The Company generally recognizes the compensation expense on a straight-line basis over the employee’s requisite service period.

Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss), adjusted for changes in income or loss that resulted from the assumed conversion of convertible shares, by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period.

The Company had the following potential common stock equivalents as of September 30, 2016 and 2015:


As of	September 30, 2016	September 30, 2015
Common stock warrants, exercise price range of $1.00-$2.00	777,981	-
Conversion feature on convertible notes, exercise price of $2.50	920,000	120,000
Conversion feature on Series B preferred stock, exercise price of $2.50	1,733,801	535,000
Total common stock equivalents	3,431,782	655,000

Since the Company reflected a net loss during the nine and three months ended September 30, 2016 and 2015, the effect of considering any common stock equivalents would have been anti-dilutive. Therefore, a separate computation of diluted earnings (loss) per share is not presented.

Reclassification

Certain prior period amounts have been reclassified to conform to current period presentation. The reclassifications did not have an impact on net loss as previously reported.

F-9

Recent Accounting Pronouncements

In May 2014, the FASB issued a comprehensive new revenue recognition standard that will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard’s core principle (issued as ASU 2014-09 by the FASB), is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The new guidance must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. In August 2015, the FASB issued ASU No. 2015-14, which defers the effective date of ASU 2014-09 by one year, and would allow entities the option to early adopt the new revenue standard as of the original effective date. This ASU is effective for public reporting companies for interim and annual periods beginning after December 15, 2017. The Company is currently evaluating its adoption method and the impact of the standard on its condensed consolidated financial statements.

In March 2015, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption of the amendments is permitted for financial statements that have not been previously issued. The amendments should be applied on a retrospective basis, wherein the balance sheet of each individual period presented should be adjusted to reflect the period-specific effects of applying the new guidance. Upon transition, an entity is required to comply with the applicable disclosures for a change in an accounting principle. These disclosures include the nature of and reason for the change in accounting principle, the transition method, a description of the prior-period information that has been retrospectively adjusted, and the effect of the change on the financial statement line items (i.e., debt issuance cost asset and the debt liability). The Company adopted ASU 2015-03 during the period ended September 30, 2016.

In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory”, which modifies existing requirements regarding measuring inventory at the lower of cost or market. Under current inventory standards, the market value requires consideration of replacement cost, net realizable value and net realizable value less an approximately normal profit margin. The new guidance replaces market with net realizable value defined as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This eliminates the need to determine and consider replacement cost or net realizable value less an approximately normal profit margin when measuring inventory. The standard is required to be adopted for annual periods beginning after December 15, 2016, including interim periods within that annual period. The amendment is to be applied prospectively with early adoption permitted. The Company is in the process of evaluating the effect of the new guidance on its condensed consolidated financial statements and disclosures.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” Under ASU 2016-02, lessees will be required to recognize, for all leases of 12 months or more, a liability to make lease payments and a right-of-use asset representing the right to use the underlying asset for the lease term. Additionally, the guidance requires improved disclosures to help users of financial statements better understand the nature of an entity’s leasing activities. This ASU is effective for public reporting companies for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective approach. The Company is in the process of evaluating the effect of the new guidance on its condensed consolidated financial statements and disclosures.

F-10

In April 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation” (topic 718). The FASB issued this update to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The updated guidance is effective for annual periods beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company is currently evaluating the impact of the new standard.

In April 2016, the FASB issued ASU No. 2016-10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing” (topic 606). In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross verses Net)” (topic 606). These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, “Revenue from Contracts with Customers”. The amendments in ASU 2016-10 provide clarifying guidance on materiality of performance obligations; evaluating distinct performance obligations; treatment of shipping and handling costs; and determining whether an entity's promise to grant a license provides a customer with either a right to use an entity's intellectual property or a right to access an entity's intellectual property. The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The adoption of ASU 2016-10 and ASU 2016-08 is to coincide with an entity's adoption of ASU 2014-09, which we intend to adopt for interim and annual reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact of the new standard.

In May 2016, the FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients”, which narrowly amended the revenue recognition guidance regarding collectability, noncash consideration, presentation of sales tax and transition and is effective during the same period as ASU 2014-09. The Company is currently evaluating the impact of the new standard.

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017. The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently in the process of evaluating the impact of ASU 2016-15 on its consolidated financial statements.

Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying consolidated financial statements.

PROPERTY AND EQUIPMENT

Property and equipment on September 30, 2016 and December 31, 2015 are as follows:


	September 30, 2016		December 31, 2015
Machinery and Equipment	$	775,422	$	175,583

Less: Accumulated Depreciation		90,158		2,790
	$	685,264	$	172,793

F-11

Depreciation expense charged to income for the nine months ended September 30, 2016 and 2015 amounted to $87,368 and $0, respectively. Depreciation expense charged to income for the three months ended September 30, 2016 and 2015 amounted to $38,383 and $0, respectively.

INVESTMENT IN NON-PUBLICLY TRADED COMPANY

During the fourth quarter of 2015, the Company issued convertible promissory notes to an accredited investor for an aggregate total of 60,000 shares of stock in a non-publicly traded company which it valued at $720,000 based on the subsequent sale of a portion of those shares during the period for $12 per share. The Company sold 20,000 and 40,000 shares in November 2015 and February 2016, respectively, for approximately $240,000 and $480,000, respectively, resulting in a reduction of the investment. As of September 30, 2016, the balance of the investment was $0.

The following table summarizes the activity for the investment in non-publicly traded company:


	September 30, 2016
Balance at January 1, 2016	$	480,000
Additions – stock of non-publicly traded company		-
Disposal – sale of stock of non-publicly traded company		(480,000)
Balance at September 30, 2016	$	-

CONVERTIBLE NOTES PAYABLE

In April 2013, the Company borrowed $100,000 in exchange for a 4% convertible promissory note due April 30, 2015 and a five-year warrant to purchase 50,000 shares of common stock at $2 each. The note is convertible at any time prior to maturity at the option of the holder at $2 per share of common stock (50,000 shares). The relative fair value of the warrant issued was $32,525 based on the Black-Scholes option pricing model. The relative fair value of the warrant was recorded as a discount and is being amortized over two years based on the effective interest method. The unamortized discount at September 30, 2016 and December 31, 2015 was $0 and $0, respectively. The note requires interest payments semi-annually. In April 2015, the note and the related warrants were extended for an additional two year period maturing in April 2017. The debt modification was evaluated under ASC 470-50, “Debt Modification and Extinguishments”. The Company determined that it was appropriate to account for the term extension on a prospective basis and the carrying amount of the debt remained unchanged. All costs incurred with third parties directly related to the maturity extension were expensed as incurred.

During the third and fourth quarters of 2015, the Company borrowed an aggregate of $1.3 million in exchange for 4% convertible notes (the “4% Convertible Notes”) with the following terms: (i) maturing on October 1, 2018 ($300,000) and November 1, 2018 ($1,000,000); (ii) quarterly cash interest due of 4%; (iii) convertible into common stock at any time at the holder’s option at $2.50 per share; and (iv) automatically convertible into common stock after May 5, 2017 at $2.50 per share if after that date the common stock trades above that price for 20 trading days with an average daily volume of 25,000 shares. As discussed in Note 8, $1.0 million was borrowed from a related party.

During the fourth quarter of 2015, the Company issued 4% Convertible Notes in the aggregate principal amount of $900,000 in exchange for 60,000 shares of stock in a non-publicly traded company valued at $15 per share (discussed in Note 4). Upon issuance of the notes, a debt discount of $180,000 was recorded for the value of the common shares of the non-publicly traded company and is being amortized using the effective interest method. The amortization of debt discount is included as a component of interest expense in the condensed consolidated statements of operations. There was an aggregate unamortized debt discount of $129,519 and $173,782 as of September 30, 2016 and December 31, 2015, respectively.

F-12

FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company follows the provisions of ASC 820 for fair value measurements of its financial assets and liabilities. The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The accounting standard established a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. This hierarchy prioritizes the inputs into three broad levels, as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the Company's own assumptions used to measure assets and liabilities at fair value. An asset or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

COMMITMENTS AND CONTINGENCIES

Operating Lease

In June 2012, the Company entered into an operating lease for its office space for $3,103 per month through June 2015, with a three year renewal option extending to June 2018. The future minimum rental payments to be paid under the non-cancelable operating lease in effect at March 31, 2015 was $9,309. In April 2015, the Company and the landlord agreed to extend and expand that lease agreement by increasing the size of the space rented. The annual rent according to the amended lease is $91,050 per year payable in equal monthly installments of $7,587, plus the Company’s share of common area maintenance charges and electricity. The amended lease is subject to a five-year extension at the election of the Company.

Employment Agreement

Mr. Ilan Reich is employed pursuant to an agreement as President, CEO and Chairman of the Company. Additionally, he will serve as Chief Financial Officer until the Board appoints a replacement. The term of his employment is to December 31, 2022 with automatic renewal for 2 year terms unless either party provides written notice. For now, Mr. Reich will not receive a base salary but will receive up to a US$5,000,000 bonus upon the achievement of the Milestone Goals. “Milestone Goals” shall mean (i) positive Earnings Before Interest Taxes Depreciation and Amortization, or EBITDA, for the Company’s last fiscal year, as reflected in the Company’s Annual Report on Form 10-K, and (ii) gross revenues of more than $20,000,000 for the Company’s last fiscal year, as reflected in the Company’s Annual Report on Form 10-K. The bonus will be paid in stock, to Mr. Reich, or in his sole discretion, fully or partially to employees and/or officers of the Company, in such amounts (up to the total amount of the bonus) and to such employees and/or officers as designated by Mr. Reich in writing to the Company. Mr. Reich is reimbursed by the Company up to $105,000 in calendar year 2016 which amount shall be increased by 5% (compounding) in each subsequent calendar year during the term of the Agreement for office, travel, entertainment, insurance (health, automobile or otherwise), automobile and other expenses arising during the term of the agreement. Additionally, Mr. Reich shall be eligible to participate in incentive, stock purchase, savings, retirement (401K) and welfare benefit plans including, without limitation, health, medical, dental, vision, life (including accidental death and dismemberment) and disability insurance plans. The Company cannot terminate Mr. Reich’s employment without cause. Mr. Reich may resign on 30 days’ notice to the Company. Mr. Reich is entitled to payment of the balance of his contract on resignation for death or disability, good reason or following a Change in Control (defined in the agreement as the accumulation by any individual of 10% or more of the shares of the Company whether by merger, consolidation, sale or other transfer). Additionally, the employment agreement provides a non-compete/non-solicitation provision for a 12 month period following the termination of Mr. Reich’s employment with the Company.

F-13

RELATED PARTY TRANSACTIONS

In December 2014, the Company borrowed an aggregate of $50,000 in exchange for an interest free demand note from a former member of the board of managers. The loan was repaid in January 2015.

In January 2015, the Company borrowed an aggregate of $50,000 in exchange for an interest free demand note from a former member of the board of managers. In addition, the Company issued warrants to purchase 50,000 shares of common stock at $1.00 per share to the lender. The warrants expire in 2020. The relative fair value of the warrant issued was $31,149 based on the Black-Scholes option pricing model. As a result of this transaction, the Company recorded a debt discount and corresponding amortization expense of $31,149. The loan was repaid in January 2015.

In October 2015, the Company sold a 4% Convertible Note in the principal amount of $1,000,000 to a related party. See Note 5.

STOCKHOLDERS’ EQUITY (DEFICIT)

The Company’s capital structure consists of the authorization to issue 100,000,000 shares of common stock and 20,000,000 shares of Preferred Stock, which may be issued in series as designated by the Board of Directors. Each series of Preferred Stock shall have such voting and other rights as designated at the time of establishment by the Board of Directors.

Each issued share of common stock and Series A Preferred Stock has one vote and the approval of a majority of the Series A Preferred Stock, voting as a separate class, is required to approve any corporate action requiring shareholder approval. The Series A Preferred Stock is entitled to participate in dividends, rights issuances and property distributions on the same terms that the Class B member units had since the formation of the Company; namely, 20% of the dividends, rights and property distributed to common stockholders. Upon liquidation of the Company, the Series A Preferred Stock is entitled to 20% of the liquidation value, subject to a priority $13,470,000 allocation to the common shares. This formulation preserves the right of the former Class B member units to participate in profits once the holders of Class A member units recouped their aggregate capital contributions.

During January 2015, the Company received $611,939 for the payoff of notes originally issued to purchase common stock and all accrued interest.

In January 2015, the Company entered into an equity financing agreement with a third party who committed to raise an aggregate of $1.5 million by February 28, 2016. This commitment was satisfied through (a) the sale of an aggregate of 697,000 shares of common stock to accredited investors for proceeds of $1,009,125 (for an average price of $1.45 per share) net of offering costs of $134,750, and (b) the exchange of 4% Convertible Notes for stock of a non-publicly traded company (See Note 4).

During February 2016, the Company raised approximately $4.2 million of cash through the sale of approximately 1.7 million shares of a new class of Preferred Stock designated as “Series B Preferred Stock”. The shares of Series B Preferred Stock:

F-14

have a stated value of $2.50 and a conversion price of $2.50, subject to certain adjustments;

are convertible into such number of shares of common stock as determined by dividing the number of shares of Series B Preferred Stock being converted, multiplied by the stated value, divided by the conversion price then in effect;

are entitled to one vote for each share of Series B Preferred Stock on any matter submitted to holders of common stock;

are entitled to dividends at the annual rate of 9.5% (which will increase to 12% in the event that by June 30, 2018, the Company does not obtain CE Mark approval of its Therapeutic Oncopheresis System and generate at least $600,000 of gross profit in two fiscal quarters, subject to certain conditions), payable quarterly in shares of Series B Preferred Stock;

upon any liquidation, will be entitled to receive, prior to any payments in respect of the Company’s common stock, an amount equal to the stated value plus any accrued but unpaid dividends; and

beginning in 2022, will automatically convert into common stock in the event that the closing price of the common stock is at least $4.00 for 20 consecutive trading days with a minimum average trading volume of at least 25,000 shares for such period.

In conjunction with that financing the terms of the Series A Preferred Stock were amended to provide that it will not participate in dividends payable in shares of Series B Preferred Stock to the holders of the Series B Preferred Stock, and to provide that the liquidation amount payable to the holders of Series A Preferred Stock will be paid following payment of the liquidation amount due to holders of Series B Preferred Stock.

On April 1, 2016, the Company issued 75,000 shares of common stock to an employee for services rendered. The Company expensed an aggregate $125,625 as stock-based compensation relating to these shares.

During the nine months ended September 30, 2016 and 2015, the Company expensed an aggregate of $2,362,823 and $1,117,015, respectively, included in the condensed consolidated statement of operations for stock based compensation. This includes the previously mentioned $125,625, the below mentioned $1,888,287 for restricted stock, and the below mentioned $348,911 for warrants.

During the three months ended September 30, 2016 and 2015, the Company expensed an aggregate of $149,528 and $160,266, respectively, included in the condensed consolidated statement of operations for stock based compensation for services provided.

As of September 30, 2016, 4,000,000 shares of Series A Preferred Stock, 1,733,801 shares of Series B Preferred Stock and 19,495,426 shares of common stock were issued and outstanding.

See Note 2 for a description of potential common stock equivalents.

F-15

Restricted Stock

The Company periodically grants restricted stock awards to certain employees and consultants pursuant to the Company’s 2014 Incentive Plan that typically vest one to two years from their grant date. The Company recognized an aggregate of $1,888,287 in compensation expense during the nine months ended September 30, 2016, related to restricted stock awards. Stock compensation expense is recognized over the vesting period of the restricted stock. At September 30, 2016 the Company had approximately $186,898 of total unrecognized compensation cost related to non-vested restricted stock, all of which will be recognized through September 2017.


	Restricted Stock		Weighted Average Exercise Price

Non-vested – December 31, 2015		470,167	$	1.72
Granted		960,000	$	1.68
Vested		(1,064,333)	$	1.69
Forfeited/Cancelled		-	$	-
Non-vested – September 30, 2016		365,834	$	1.70

The following is a summary of the Company’s warrant activity:


	Warrants		Weighted Average Exercise Price

Outstanding – January 1, 2016		535,000	$	1.42
Exercisable –January 1, 2016		535,000	$	1.42
Granted		417,981	$	1.50
Exercised		-	$	-
Forfeited/Cancelled		(175,000)	$	-
Outstanding – September 30, 2016		777,981	$	1.42
Exercisable – September 30, 2016		777,981	$	1.42

F-16


Warrants Outstanding						Warrants Exercisable
Range of Exercise Price	Number Outstanding		Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$1.00-$2.00		777,981	3.67 years	$	1.42	777,981	$	1.42

The following table summarizes the assumptions the Company utilized to estimate the fair value of the convertible note and warrants, and derivative liability issued during the nine months ended September 30, 2016:


Assumptions		September 30, 2016

Expected term (years)		5.00
Expected volatility		86.6%
Risk-free interest rate		1.24%
Dividend yield		0.00%

The expected warrant term is based on the remaining contractual term. The expected volatility is based on historical-volatility of peer entities whose stock prices were publicly available. The risk-free interest rate is based on the U.S. Treasury yields with terms equivalent to the expected term of the related warrant at the valuation date. Dividend yield is based on historical trends.

During the nine months ended September 30, 2016, the Company issued warrants for advisory services and expensed an aggregate of $348,911 as stock based compensation.

10. SUBSEQUENT EVENTS

In October 2016, the Company borrowed $300,000 from the President and CEO of the Company pursuant to an interest-free demand note.

F-17

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statements

The following is management’s discussion and analysis of certain significant factors which have affected our financial position and operating results during the periods included in the accompanying consolidated financial statements, as well as information relating to the plans of our current management and should be read in conjunction with the accompanying financial statements and their related notes included in this Quarterly Report. References in this section to “we,” “us,” “our,” or the “Company” are to the consolidated business of Viatar CTC Solutions Inc. and its wholly owned subsidiary, Viatar LLC.

This Quarterly Report contains forward-looking statements. Generally, the words “believes,” “anticipates,” “may,” “will,” “should,” “expects,” “intends,” “estimates,” “continues,” and similar expressions or the negative thereof or comparable terminology are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including the matters set forth in this Quarterly Report or other reports or documents we file with the SEC from time to time, which could cause actual results or outcomes to differ materially from those projected. Undue reliance should not be placed on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to update these forward-looking statements except as may be required under applicable securities laws.

Overview

We are a biotechnology company focused on developing and marketing cancer molecular diagnostics and cancer therapy products, both of which are based on the principle of removing blood-borne circulating tumor cells (CTCs). We are seeking to commercialize two products which utilize our proprietary CTC removal technology:

· The Viatar ^TM Collection System for Molecular Analysis is designed to collect and purify a statistically significant quantity of CTCs from up to 50 mL of blood as the “front end” for DNA sequencing and other genetic analysis technologies used primarily for research.

· The Viatar ^TM Therapeutic Oncopheresis System is designed to remove CTCs from a patient’s blood as a new cancer therapy for metastatic disease.

We anticipate launching the Viatar^M Collection System for Molecular Analysis during 2017 once we receive the following regulatory clearances: first, a CE Mark in Europe and Canada and, second, a 510K designation in the United States. We are currently engaged in research collaborations with several prominent researchers with the goal of marketing and selling the Viatar^TM Collection System for Molecular Analysis through private label and distribution arrangements.

We anticipate launching the Viatar ^TM Therapeutic Oncopheresis System during 2017 with a CE Mark in Europe and Canada. Introduction in the United States will take several years, based on the premarket approval application (“PMA”) classification by the FDA. We anticipate marketing and selling the Viatar^TM Therapeutic Oncopheresis System on a direct basis through our own dedicated sales force in key large markets (such as the United States, Germany, France, Italy, UK and Japan), and through distributors in other markets.

Key Factors Affecting our Results of Operations and Financial Condition

Our overall long-term growth plan depends on our ability to develop and commercialize our two oncology products. We are working with several prominent researchers to optimize our Viatar^TM Collection System for Molecular Analysis to their process flow, and we intend to enter into additional such collaborations in the coming year. These activities will help facilitate market adoption of that product, and we anticipate having to complete various studies with clinical samples to demonstrate its efficacy. We will also seek to publish the results of those studies in peer-reviewed scientific journals. Our ability to complete such clinical studies, as well as to perform clinical studies for the Viatar^TM Therapeutic Oncopheresis System is dependent on our ability to foster strong collaborative relationships with cancer researchers, CTC technology platform companies, and companies which make DNA sequencing equipment or perform such services; to conduct the appropriate clinical studies; and to obtain favorable clinical data.

For the years ended December 31, 2015 and 2014, we generated $65,910 and $9,000 from commercial sales, respectively. Assuming we are successful in completing development activities for the Viatar^TM Collection System for Molecular Analysis, we expect to generate revenues during 2017 from sales of that product. However, significant revenues and growth will depend on market adoption of that product. Similarly, assuming we are successful in completing development activities for the Viatar^TM Therapeutic Oncopheresis System, we expect to generate revenues from sales of that system in 2017; however, significant revenues and growth will depend on clinical studies showing its efficacy in mitigating the spread and growth of metastatic tumors, and regulatory and reimbursement approval in the US and major European countries.

Our operating expenses consist of general and administrative; research and development; clinical and regulatory; and business development. These expenses principally consist of personnel costs, outside services (such as contract engineering firms, as well as the cost of supporting clinical studies and regulatory consultants), laboratory equipment and consumables, rent and overhead, and legal and accounting fees. We have also begun to incur significant capital costs for customized manufacturing and inspection equipment. All of these expense and capital equipment categories will increase in the near-term, principally as a result of hiring additional personnel and contracting with outside engineering firms to complete the development of our two products; expanding the range and scope of clinical trials (both with cancer researchers as well as companies we collaborate with); hiring additional personnel to handle business development, sales and marketing activities; and hiring additional personnel or outside services to handle administrative functions such as accounting, information technology and logistics.

We expect there to be an element of seasonality to our business, as research activities and patient treatment or monitoring with CTC-based tests is likely to decline during vacation and holiday seasons. We expect this trend of seasonality to continue for the foreseeable future.

Recent Developments

On October 21, 2016, the Company entered into Amendment No. 1 to the Company’s Executive Employment Agreement with Ilan Reich, the Company’s Chief Executive Officer and President. The amendment establishes certain milestones, of (i) positive Earnings Before Interest Taxes Depreciation and Amortization, or EBITDA, for the Company’s last fiscal year, as reflected in the Company’s Annual Report on Form 10-K, and (ii) gross revenues of more than $20,000,000 for the Company’s last fiscal year, for the payment of Mr. Reich’s bonus, provides that the bonus will be paid in stock, and provides that the bonus may be allocated to members of the Company’s management as designated by Mr. Reich.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of our financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates based on historical experience and make various assumptions, which management believes to be reasonable under the circumstances, which form the basis for judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The notes to our financial statements, which are included elsewhere in this report, contain a summary of our significant accounting policies. We consider the accounting policies discussed below as being critical to the understanding of our current and future results of our operations.

Revenue Recognition

We recognize revenue in accordance with ASC 605, Revenue Recognition, and ASC 954-605, Health Care Entities, Revenue Recognition - which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. For contract partners, revenue is recorded based upon the contractually agreed upon fee schedule. When assessing collectability, we consider whether we have sufficient payment history to reliably estimate a payor’s individual payment patterns.

Accounts Receivable and Bad Debts

We carry accounts receivable at original invoice amounts, less an estimate for doubtful receivables, based on a review of all outstanding amounts on a periodic basis. The estimate for doubtful receivables will be determined from an analysis of the accounts receivable on a quarterly basis, and be recorded as bad debt expense. Since we will only recognize revenue to the extent we expect to collect such amounts, bad debt expense related to receivables from product revenue will be recorded in general and administrative expense in the statements of operations. Accounts receivable will be written off when deemed uncollectible. Recoveries of accounts receivable previously written off will be recorded when received.

Stock-Based Compensation Expense

In December 2004, the Financial Accounting Standards Board (the “FASB”) issued ASC 718, Compensation – Stock Compensation, or ASC 718. Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. The Company amortizes such compensation amounts, if any, over the respective vesting periods of the award. The Company uses the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, that requires the input of highly complex and subjective variables, including the expected life of the award and the expected stock price volatility over a period equal to or greater than the expected life of the award.

Recent Accounting Pronouncements

In April 2016, the FASB issued ASU No. 2016-10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing” (topic 606). In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross verses Net)” (topic 606). These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, “Revenue from Contracts with Customers”. The amendments in ASU 2016-10 provide clarifying guidance on materiality of performance obligations; evaluating distinct performance obligations; treatment of shipping and handling costs; and determining whether an entity's promise to grant a license provides a customer with either a right to use an entity's intellectual property or a right to access an entity's intellectual property. The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The adoption of ASU 2016-10 and ASU 2016-08 is to coincide with an entity's adoption of ASU 2014-09, which we intend to adopt for interim and annual reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact of the new standard.

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated financial statements.

Results of Operations

Three Months Ended September 30, 2016 and 2015

The following table sets forth certain information concerning our results of operations for the periods shown:



	Three Months Ended September 30,				Change
	(unaudited)
	2016		2015		Dollars		Percent
Revenue
Sales	$	-		13,985		(13,985)		(100)
Cost of Revenue
Cost of Sales		-		3,830		(3,380)		(100)
Gross Profit		-		10,155		(10,155)		(100)
Expenses
Research and Development
Research and Development		840,954		523,824		317,130		61
Clinical & Regulatory		80,623		154,054		(73,431)		(48)
Total R&D		921,577		677,878		243,699		36
General and Administrative
General and Administrative		304,070		198,557		105,513		53
Business Development		115,862		45,509		70,353		155
Total G&A		419,932		244,066		175,866		72
Total Expenses		1,341,509		921,944		419,565		46
Other Income (Expenses)
Interest Expense		(52,261)		(16,413)		(35,848)		218
Total Other Income (Expense)		(52,261)		(16,413)		(35,848)		218
Loss Before Income Tax Expense		(1,393,770)		(928,202)		465,568		50
Income tax expense		(5,799)		(6,582)		783		(12)
Net Loss	$	(1,399,569)	$	(934,784)	$	464,785		50

Revenue

Sales of $0 and $13,985 for the three months ended September 30, 2016 and 2015, respectively, arose in connection with commercial sales. The decrease is attributable to no sales during the period ended September 30, 2016. We do not expect to achieve significant sales until there is a full scale commercial rollout and we successfully obtain widespread adoption by the research and medical communities.

Gross Profit

Gross profit for the three months ended September 30, 2016 was $0 or 0% of revenue, compared to $10,155 or 73% of revenue for the three months ended September 30, 2015.

Expenses

Research and Development Expenses

Research and development expenses consist of two categories of expenses: (i) research and development (“R&D”); and (ii) clinical trial and regulatory expenses.

R&D Expenses

R&D was $840,954 for the three months ended September 30, 2016, an increase of $317,130 or 61%, compared with $523,824 for the three months ended September 30, 2015. Of that $840,954 of R&D expenses for the three months ended September 30, 2016, $107,424 was attributable to the non-cash expensing of restricted and unrestricted stock awards to employees and consultants issued pursuant to the Company’s 2014 Equity Incentive Plan (“2014 Equity Incentive Plan”), compared to $160,266 for the three months ended September 30, 2015. The balance of R&D expenses for the three months ended September 30, 2016 and 2015 was $760,023 and $363,558, respectively. The increase was due to higher staffing levels, use of third party engineering resources, and the purchase of supplies and equipment to support the oncology program.

Clinical Trial and Regulatory Expenses

Clinical trial and regulatory expenses were $80,623 for the three months ended September 30, 2016, a decrease of $73,431, or 48%, compared with $154,054 for the three months ended September 30, 2015. Of that $80,623 of clinical trial and regulatory expenses for the three months ended September 30, 2016, $54,129 was attributable to the non-cash expensing of restricted and unrestricted stock awards to employees and consultants issued pursuant to the 2014 Equity Incentive Plan, compared to $0 for the three months ended September 30, 2015. The balance of $54,129 was due to expenses in preparation for upcoming clinical trials for the Company’s Therapeutic Oncopheresis System.

General and Administrative Expenses

General and administrative expenses consist of general and administrative (“G&A”) and business development expenses.

G&A Expenses

G&A expenses were $304,070 for the three months ended September 30, 2016, an increase of $105,513 or 53%, compared to $198,557 for the three months ended September 30, 2015. The increase was due primarily to the non-cash stock based compensation totaling $42,104 during the current period compared to $0 in the prior period.

Business Development Expenses

Business development expenses were $115,862 for the three months ended September 30, 2016, an increase of $70,353 or 155%, compared with $45,509 for the three months ended September 30, 2015. The increase was due to higher costs to obtain new capital, including certain investor relation activities and meetings.

Interest Expense

Interest expense was $52,261 for the three months ended September 30, 2016, compared to $16,413 for the three months ended September 30, 2015. Interest expense for the period ended September 30, 2016 is comprised of $15,219 of accrued interest in the outstanding NYC R&D tax credit appeal, $14,862 for non-cash amortization of debt discount related to warrants issued with convertible notes, and $22,181 of accrued interest on debt. Interest expense for the period ended September 30, 2015 was comprised of $14,123 of accrued interest in the outstanding NYC R&D tax credit appeal and $2,290 of accrued interest on debt.

Net Loss

Net loss was $1,399,569 for the three months ended September 30, 2016, an increase of $464,785 or 50%, compared to $934,784 for the three months ended September 30, 2015. The increase was primarily due to higher expenses as discussed above.

Nine Months Ended September 30, 2016 and 2015

The following table sets forth certain information concerning our results of operations for the periods shown:



	Nine Months Ended September 30,				Change
	(unaudited)
	2016		2015		Dollars		Percent
Revenue
Sales		-		37,940		(37,940)		(100)
Cost of Revenue
Cost of Sales		-		7,660		(7,660)		(100)
Gross Profit		-		30,280		(30,280)		(100)
Expenses
Research and Development
Research and Development		3,315,874		1,732,079		1,583,795		91
Clinical & Regulatory		240,703		157,077		83,626		53
Total R&D		3,556,577		1,889,156		1,667,421		88
General and Administrative
General and Administrative		2,270,767		748,781		1,521,986		203
Business Development		365,821		192,753		173,068		90
Total G&A		2,636,588		941,534		1,695,054		180
Total Expenses		6,193,165		2,830,690		3,362,475		119
Other Income (Expenses)
Dividend Income		3,227		-		3,227		100
Interest Expense		(168,994)		(73,132)		(95,862)		131
Total Other Income (Expense)		(165,767)		(73,132)		(92,635)		127
Loss Before Income Tax Expense		(6,358,932)		(2,873,542)		(3,485,390)		121
Income tax expense		(6,750)		(6,582)		(168)		3
Net Loss	$	(6,365,682)		(2,880,124)		(3,485,558)		121

Revenue

Sales of $0 and $37,940 for the nine months ended September 30, 2016 and 2015, respectively, arose in connection with commercial sales. The decrease is attributable to no sales during the period ended September 30, 2016. We do not expect to achieve significant sales until there is a full scale commercial rollout and we successfully obtain widespread adoption by the research and medical communities.

Gross Profit

Gross profit for the nine months ended September 30, 2016 was $0 or 0% of revenue compared to $30,280 or 80% of revenue for the nine months ended September 30, 2015.

Expenses

Research and Development Expenses

Research and development expenses consist of two categories of expenses: (i) research and development (“R&D”); and (ii) clinical trial and regulatory expenses.

R&D Expenses

R&D was $3,315,874 for the nine months ended September 30, 2016, an increase of $1,583,795 or 91%, compared with $1,732,079 for the nine months ended September 30, 2015. Of that $3,315,874 of R&D expenses for the nine months ended September 30, 2016, $923,642 was attributable to the non-cash expensing of restricted and unrestricted stock awards to employees and consultants issued pursuant to the Company’s 2014 Equity Incentive Plan (“2014 Equity Incentive Plan”), compared to $857,515 for the nine months ended September 30, 2015. The balance for the nine months ended September 30, 2016 and 2015 was $2,392,232 and $874,564 respectively. The increase was due to higher staffing levels, use of third party engineering resources, and the purchase of supplies and equipment to support the oncology program.

Clinical Trial and Regulatory Expenses

Clinical trial and regulatory expenses were $240,703 for the nine months ended September 30, 2016, an increase of $83,626 or 53%, compared with $157,077 for the nine months ended September 30, 2015. Of that $240,703 of clinical trial and regulatory expenses for the nine months ended September 30, 2016, $91,790 was attributable to the non-cash expensing of restricted and unrestricted stock awards to employees and consultants issued pursuant to the 2014 Equity Incentive Plan compared to $0 for the nine months ended September 30, 2015. The balance of $148,912 was due to expenses in preparation for upcoming clinical trials for the Company’s Therapeutic Oncopheresis System.

General and Administrative Expenses

General and administrative expenses consist of general and administrative (“G&A”) and business development expenses.

G&A Expenses

G&A expenses were $2,270,767 for the nine months ended September 30, 2016, an increase of $1,521,986 or 203%, compared to $748,781 for the nine months ended September 30, 2015. The increase was due primarily to the non-cash stock based compensation totaling $1,347,391 during the current period, compared to $225,000 in the prior period.

Business Development Expenses

Business development expenses were $365,821 for the nine months ended September 30, 2016, an increase of $173,068 or 90%, compared with $192,753 for the nine months ended September 30, 2015. The increase was due to higher costs to obtain new capital, including certain investor relation activities and meetings.

Interest Expense

Interest expense was $168,994 for the nine months ended September 30, 2016, compared to $73,132 for the nine months ended September 30, 2015. Interest expense for the period ended September 30, 2016 is comprised of $44,816 of accrued interest in the outstanding NYC R&D tax credit appeal, $44,262 for non-cash amortization of debt discount related to warrants issued with convertible notes, and $79,916 of accrued interest on debt. Interest expense for the period ended September 30, 2016 was offset by dividend income of $3,227 from the Company’s investment in a non-publicly traded company. Interest expense for the period ended September 30, 2015 was primarily comprised of $30,088 of accrued interest in the outstanding NYC R&D tax credit appeal, $37,654 for non-cash amortization of debt discount related to warrants issued with a demand note, and $5,390 of accrued interest on debt.

Net Loss

Net loss was $6,365,682 for the nine months ended September 30, 2016, an increase of $3,485,558 or 121%, compared to $2,880,124 for the nine months ended September 30, 2015. The increase was primarily due to the higher expenses as discussed above.

Liquidity and Capital Resources

Since inception, the Company has not generated significant revenues. As a result, we have incurred significant net losses and significant negative cash flows from operations.

We are actively working to improve our financial position and enable the growth of our business by raising new capital. During the nine months ended September 30, 2016 and 2015 we raised $4,199,240 and $1,009,125, respectively, through equity financing and $0 and $350,000, respectively, through debt financing. In addition, we received $0 and $611,939 from the promissory note used for common stock subscription during the nine months ended September 30, 2016 and 2015, respectively. We repaid $0 and $100,000, respectively, on two outstanding demand notes during the nine months ended September 30, 2016 and 2015, respectively.

We have a limited operating history and our business is subject to all of the usual risks inherent in establishing and growing a new business enterprise. If we continue to incur operating losses and fail to become a profitable company, we may be unable to continue our operations. We expect to continue to operate at a net loss until we can obtain regulatory approval to commercialize our Therapeutic Oncopheresis System and secure widespread market acceptance and favorable reimbursement rates. While we currently have sufficient cash on hand to fund operating and capital expenses for the remainder of this year, we anticipate that we will need substantial additional capital of approximately $8-15 million in order to achieve commercialization and subsequent profitability.

In January 2015, we received a commitment from an existing shareholder to provide $1.5 million of financing by February 28, 2016. This commitment was satisfied through (a) the sale of an aggregate of 697,000 shares of common stock to accredited investors for proceeds of $1,009,125 (for an average price of $1.45 per share) net of offering costs of $134,750, and (b) the exchange of 4% Convertible Notes for stock of a non-publicly traded company.

In October 2015, the Company borrowed $1,000,000 from a related party in exchange for a 4% convertible promissory note due November 2018. In October 2015, the Company issued a 4% convertible promissory note of $900,000 due December 2018 in exchange for 60,000 shares of stock in a non-publicly company valued at $15 per share, which was monetized in February 2016.

During the nine month ended September 30, 2016, the Company raised approximately $4.2 million of cash through the sale of approximately 1.7 million shares of Series B Preferred Stock. The investors are existing, accredited shareholders of the Company.

The Company anticipates raising substantial additional capital in the fourth quarter of 2016 and first quarter of 2017, either in the form of equity, debt or convertible instruments, as well as the issuance of warrants to purchase common stock with a cashless exercise feature (that will not provide new capital upon exercise).

Cash Flows

Cash Used in Operating Activities

Net cash used in operating activities was $3,957,586 for the nine months ended September 30, 2016, compared to net cash used in operating activities of $1,794,983 for the nine months ended September 30, 2015. The change in cash used in operating activities was a result of the overall increase in expenses described above.

In all periods, the primary use of cash in operating activities was to fund operations. The Company’s monthly cash burn rate during most of 2016 has been approximately $500,000, which is the appropriate level needed to complete the manufacturing scale-up and regulatory compliance activities necessary to commence the first human clinical trial in 2017. Since September 2016, the Company has reduced its monthly cash burn rate to approximately $250,000 in order to conserve cash pending the completion of various new financing endeavors. This reduction in the spending rate may cause a delay in completion of the Company’s research and development program.

Cash Provided by Investing Activities

During the nine months ended September 30, 2016, the Company received net proceeds of $480,000 from the sale of the investment in a non-publicly traded company. The increase in cash was offset by $599,839 utilized for the purchase of equipment and machinery for full-scale production of components for our Therapeutic Oncopheresis System. There was no cash provided by or used in investing activities in 2015.

Cash Provided by Financing Activities

Net cash provided by financing activities was $4,199,240 for the nine months ended September 30, 2016, compared to net cash provided by financing activities of $1,871,064 for the nine months ended September 30, 2015. Our primary source of financing in all periods consisted of equity capital contributed by current and new investors, as well as debt financing from various lenders.

Contingencies

The Company is currently under audit by New York City tax authorities for the 2011, 2012, and 2013 tax years. The Company applied for New York City biotechnology tax credits and received certificates of eligibility from the NYC Department of Finance in the amounts of $147,997, $242,016, and $236,874 for tax years 2013, 2012, and 2011, respectively. These credits have been recognized as income tax benefits on the consolidated statements of operations in the year of application. The Company received refunds for these amounts in previous years. The City of New York subsequently ruled that the Company does not qualify for the tax credits. As of September 30, 2016, the Company accrued $821,842 on the condensed consolidated balance sheet which includes $194,955 of interest at the statutory rate. The Company appealed the decision made by the City of New York. While settlement discussions have been held, as of the date of this report no decision has been made regarding the appeal or settlement.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not required for a smaller reporting company.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

The Company maintains a set of disclosure controls and procedures designed to ensure that information required to be disclosed by the Company in the reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified by the SEC's rules and forms. Disclosure controls are also designed with the objective of ensuring that this information is accumulated and communicated to the Company's management, including the Company's chief executive officer and chief financial officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Pursuant to Rule 13a-15(b) under the Exchange Act, the Company carried out an evaluation with the participation of the Company’s management, including Ilan Reich, the Company’s chief executive officer and chief financial officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of September 30, 2016. Based upon that evaluation, the Company’s chief executive officer and chief financial officer concluded that the Company’s disclosure controls and procedures were not effective due to the deficiencies in the Company’s internal control over financial reporting identified below.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. Based on management's assessment over financial reporting, management believes as of September 30, 2016, the Company's internal control over financial reporting was not effective due to the following deficiencies:

(i)

there are limited controls over information processing due to limited resources,

(ii)

a lack of sufficient internal accounting expertise to provide reasonable assurance that our financial statements and notes thereto are prepared in accordance with GAAP, and

(iii)

a lack of segregation of duties to ensure adequate review of financial statement preparation.

Accordingly, as the result of identifying the above material weaknesses, we have concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the Company's internal controls.

Management believes that the material weaknesses set forth above were the result of the scale of our operations and are intrinsic to our small size. Management believes these weaknesses did not have a material effect on our financial results and intends to take remedial actions upon receiving substantial additional funding for the Company's business operations.

Changes in Internal Controls over Financial Reporting

We regularly review our system of internal control over financial reporting and make changes to our processes and systems to improve controls and increase efficiency, while ensuring that we maintain an effective internal control environment. Changes may include such activities as implementing new, more efficient systems, consolidating activities, and migrating processes.

There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

We are not party to, and our property is not the subject to, any material legal proceedings.

Item 1A. Risk Factors

Not required for a smaller reporting company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In July 2016, the Company issued an aggregate of 40,114.8 shares of Series B Preferred Stock to holders of the Company’s shares of Series B Preferred Stock as dividends.

In connection with the foregoing, the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.




Exhibit No.	Description

10.1	Amendment No. 1 to Executive Employment Agreement between the Company and Ilan Reich.*
31.1	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

32.1	Certification of the Principal Executive Officer and Principal Financial Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

101.INS		XBRL Instance Document*

101.SCH		XBRL Taxonomy Extension Schema Document*

101.CAL		XBRL Taxonomy Calculation Linkbase Document*

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document*

101.LAB		XBRL Taxonomy Label Linkbase Document*

101.PRE		XBRL Taxonomy Presentation Linkbase Document*

*Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.




	VIATAR CTC SOLUTIONS INC.

Date: November 14, 2016	By:	/s/ Ilan Reich
		Ilan Reich
		President, Chief Executive Officer and Chief Financial Officer
		(Principal Executive Officer and Principal Accounting and Financial Officer)

EX-101.INS 2 vrtt-20160930.xml XBRL INSTANCE DOCUMENT

0.001

11000000

0.001

100000000

19495426

18605426

37940

13985

7660 3830

30280

10155

3556577

1889156

921577

677878

2636588

941534

419932

244066

6193165

2830690

1341509

921944

-1693165

-2830690

-1341509

-921944

3227

-168994

-73132

-52261

-16413

-6358932

-2873542

-1393770

-928202

-6750

-6582

-5799

-6582

-1399569

-934784

-45

-393

-11

-120

-6365637 -2879731 -1399558 -934664 -239051 -103790 -6604688 -2879731 -1503348 -934664

-0.34

-0.16

-0.08

-0.05

19196594

17604366

19495426

17981054

630260

508445

19679

247659

649939

756104

685264

172793

480000

1335203

1408897

385548

368116

626887

100000

1112435

995003

2070481

2126218

3182916

3121221

4000 4000 1734

19496

18606

26959694

20492974

-28822215

-22217527

-1837291

-1701947

-10422

-10377

-1847713

-1712324

1335203

1408897

-6365682

-2880124

2362823

1117015

44263

37654

87368

-86358

-69528

-1794983

480000

-599839

-119839

50000

-100000 300000 611939

1009125

4199240

1871064

121815

76081

508445

31351

630260

107432

54734

4291

31149

135261 103790 10-Q 2016-09-30 false Viatar CTC Solutions Inc. 0001616495 vrtt --12-31 19495426 Smaller Reporting Company Yes No No 2016 Q3

1.             NATURE OF OPERATIONS   Viatar CTC Solutions Inc., formerly known as Vizio Medical Devices LLC (Vizio), and Subsidiary (as defined below) is a pre-clinical stage company focused on medical devices for oncology applications which remove circulating tumor cells for diagnostic and therapeutic purposes.   Vizio was a Delaware limited liability company with perpetual duration that was formed on December 18, 2007. On February 25, 2014, Vizio converted to a Delaware C corporation and changed its name to Viatar CTC Solutions Inc. (Viatar CTC Solutions).   Viatar CTC Solutions conducts all of its operations through its subsidiary, Viatar LLC (the Subsidiary). The Subsidiary was formed on September 23, 2010 as a Delaware limited liability company with perpetual duration.   Viatar CTC Solutions and Vizio are together referred to as the Company.   Since inception, the Company has not generated significant revenues. As a result, we have incurred significant net losses and significant negative cash flows from operations.   As reflected in the accompanying condensed consolidated financial statements, the Company incurred a net loss and net cash used in operations of $6,365,682 and $3,957,586, respectively, for the nine months ended September 30, 2016. As of September 30, 2016 the Company had a working capital deficit of $462,496 and an accumulated deficit of $28,822,215.  These conditions raise substantial doubt about the Companys ability to continue as a going concern. The Companys continued existence is dependent upon several factors, including (a) obtaining funding, whether in the form of equity, or debt investments, licensing revenues, strategic collaboration payments or grants from government or other sources, (b) success in achieving its research and development goals, (c) obtaining regulatory approvals, and (d) gaining market acceptance and/or distribution or strategic partners for its products. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.   The Company has raised approximately $21,700,000 of capital since its inception, including $20.3 million from the sale of common and Series B Preferred stock, $1.4 million from convertible notes and $100,000 of demand notes. Management is continually pursuing additional funding sources.

2.             Summary of Significant Accounting Policies   Basis of Accounting   The accompanying unaudited condensed consolidated financial statements have been prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (GAAP).   The financial statements contained herein have been prepared by the Company in accordance with GAAP for interim financial information. Accordingly, they do not include all information and footnotes required by GAAP for complete financial statements. The balance sheet at December 31, 2015 was derived from audited financial statements but does not include all disclosures required by GAAP. In the opinion of management, the interim financial statements include all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of the results of the periods presented. The results of operations for the nine and three months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto for the year ended December 31, 2015.   Principles of Consolidation   The accompanying condensed consolidated financial statements include the accounts of Viatar CTC Solutions Inc., the Subsidiary and amounts related to a noncontrolling interest in the Subsidiary. The noncontrolling interest represents a 0.001% ownership interest in the Subsidiary at September 30, 2016 and December 31, 2015. All significant intercompany accounts and transactions have been eliminated in consolidation.   Use of Estimates   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Significant estimates subject to such estimates and assumptions include the valuation of debt and equity instruments issued for services and in connection with agreements and contracts entered in to by the Company. Actual results could differ from those estimates.   Cash   The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents. The Company held no cash equivalents at September 30, 2016 or December 31, 2015.   The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits.   Fair Value of Financial Instruments   The Companys financial instruments consist of cash, accounts payable and accrued expenses. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of September 30, 2016 and December 31, 2015, the carrying amount of cash, accounts payable and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.   Property and Equipment   Property and equipment are recorded at cost. Depreciation expense is computed using straight-line methods over the estimated useful lives.   Asset lives for financial statement reporting of depreciation are:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr align="left"> <td width="60%" valign="top" style='width:60.0%;padding:0'> Machinery and equipment </td> <td width="2%" valign="top" style='width:2.0%;padding:0'>   </td> <td width="38%" valign="top" style='width:38.0%;padding:0'> 5 years </td> </tr> </table> </div>   Cost-Method Investment   The Companys cost-method investment in a non-publicly traded company is included in the condensed consolidated balance sheets and is carried at cost, adjusted for any impairment, because the Company does not have a controlling interest and does not have the ability to exercise significant influence over this company. The Company monitors any such investment for impairment on a quarterly basis, and adjusts carrying value for any impairment charges recognized. Realized gains and losses on this investment are reported in other income (expense), net in the condensed consolidated statements of operations.   As of September 30, 2016 the Company does not have any investment in any non-publicly traded company. See Note 4.   Revenue Recognition   The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the product is delivered, (3) the sales price to the customer is fixed or determinable, and (4) collectability of the related customer receivable is reasonably assured. There is no stated right of return for products. The Company generally meets these criteria upon shipment.   Cost of Sales   Cost of sales represents costs directly related to the production and manufacturing of the Companys products for commercial sale to customers. Costs include product cost, freight, packaging, and labor costs.   Research and Development   Research and development costs consist of ongoing testing (including pre-clinical and clinical), research and development, and are expensed as incurred.   Derivatives   The Company evaluated its options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, Derivatives and Hedging. The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassed to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liability at the fair value of the instrument on the reclassification date.   Income Taxes   In the ordinary course of business, there is inherent uncertainty in quantifying income tax positions. The Company assesses its income tax positions and records tax assets or liabilities for all years subject to examination based upon managements evaluation of the facts and circumstances and information available at the reporting dates. For those tax positions where it is more-likely-than-not that a tax benefit will be sustained, we have recorded the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more-likely-than-not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. The Company records interest and penalties related to uncertain tax positions as a component of income tax expense or benefit.   The Company files income tax returns with the U.S. federal government and various state and local jurisdictions. The Company is no longer subject to tax examinations by tax authorities for years prior to 2012.   The Company is currently under audit by New York City tax authorities for the 2011, 2012, and 2013 tax years. The Company applied for New York City biotechnology tax credits and received certificates of eligibility from the NYC Department of Finance in the amounts of $147,997, $242,016, and $236,874 for tax years 2013, 2012, and 2011, respectively. The Company received refunds for these amounts in previous years. The City of New York subsequently ruled that the Company does not qualify for the tax credits. As of September 30, 2016, the Company accrued $626,887 on the condensed consolidated balance sheets, as well as $194,955 of interest at the statutory rate, which is included in accounts payable and accrued expenses on the condensed consolidated balance sheets. The Company appealed the decision made by the City of New York. While settlement discussions have been held, as of the date of this report no decision has been made regarding the appeal or settlement.   Commitments and Contingencies   The Company follows subtopic 450-20 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) to report accounting for contingencies. Certain conditions may exist as of the date the condensed consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.    If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Companys condensed consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.   Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.   Stock-Based Compensation   In December 2004, the FASB issued ASC 718, Compensation Stock Compensation, or ASC 718. Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. The Company amortizes such compensation amounts, if any, over the respective vesting periods of the award. The Company uses the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, that requires the input of highly complex and subjective variables, including the expected life of the award and the expected stock price volatility over a period equal to or greater than the expected life of the award.   Equity instruments (Instruments) issued to anyone other than employees are recorded on the basis of the fair value of the Instruments, as required by ASC 718. ASC 505, Equity Based Payments to Non-Employees, or ASC 505, defines the measurement date and recognition period for such Instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the Instruments are vested. The measured value related to the Instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.   The Company recognizes the compensation expense for all share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. The Company generally recognizes the compensation expense on a straight-line basis over the employees requisite service period.   Earnings (Loss) Per Share   Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss), adjusted for changes in income or loss that resulted from the assumed conversion of convertible shares, by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period.   The Company had the following potential common stock equivalents as of September 30, 2016 and 2015:     <table border="0" cellspacing="0" cellpadding="0" width="595" style='margin-left:.5in;border-collapse:collapse'> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;padding:0in 0in 1.5pt 0in'> As of </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="11" valign="bottom" style='width:8.3pt;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;padding:0'> September 30, 2016 </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="70" valign="bottom" style='width:52.6pt;padding:0'> September 30, 2015 </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;padding:0in 0in 1.5pt 0in'> Common stock warrants, exercise price range of $1.00-$2.00 </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="11" valign="bottom" style='width:8.3pt;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;padding:0'> 777,981 </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="70" valign="bottom" style='width:52.6pt;padding:0'> - </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;background:#CCEEFF;padding:0'> Conversion feature on convertible notes, exercise price of $2.50 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> <td width="11" valign="bottom" style='width:8.3pt;background:#CCEEFF;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;background:#CCEEFF;padding:0'> 920,000 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> <td width="70" valign="bottom" style='width:52.6pt;background:#CCEEFF;padding:0'> 120,000 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> </tr> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;background:white;padding:0in 0in 1.5pt 0in'> Conversion feature on Series B preferred stock, exercise price of $2.50 </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="11" valign="bottom" style='width:8.3pt;background:white;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:white;padding:0'> 1,733,801 </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="70" valign="bottom" style='width:52.6pt;border:none;border-bottom:solid windowtext 1.0pt;background:white;padding:0'> 535,000 </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>  Total common stock equivalents </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>   </td> <td width="11" valign="bottom" style='width:8.3pt;background:#CCEEFF;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> 3,431,782 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>   </td> <td width="70" valign="bottom" style='width:52.6pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> 655,000 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>   </td> </tr> </table>   Since the Company reflected a net loss during the nine and three months ended September 30, 2016 and 2015, the effect of considering any common stock equivalents would have been anti-dilutive. Therefore, a separate computation of diluted earnings (loss) per share is not presented.   Reclassification   Certain prior period amounts have been reclassified to conform to current period presentation. The reclassifications did not have an impact on net loss as previously reported.   Recent Accounting Pronouncements   In May 2014, the FASB issued a comprehensive new revenue recognition standard that will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standards core principle (issued as ASU 2014-09 by the FASB), is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The new guidance must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. In August 2015, the FASB issued ASU No. 2015-14, which defers the effective date of ASU 2014-09 by one year, and would allow entities the option to early adopt the new revenue standard as of the original effective date. This ASU is effective for public reporting companies for interim and annual periods beginning after December 15, 2017. The Company is currently evaluating its adoption method and the impact of the standard on its condensed consolidated financial statements.   In March 2015, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption of the amendments is permitted for financial statements that have not been previously issued. The amendments should be applied on a retrospective basis, wherein the balance sheet of each individual period presented should be adjusted to reflect the period-specific effects of applying the new guidance. Upon transition, an entity is required to comply with the applicable disclosures for a change in an accounting principle. These disclosures include the nature of and reason for the change in accounting principle, the transition method, a description of the prior-period information that has been retrospectively adjusted, and the effect of the change on the financial statement line items (i.e., debt issuance cost asset and the debt liability). The Company adopted ASU 2015-03 during the period ended September 30, 2016.   In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, which modifies existing requirements regarding measuring inventory at the lower of cost or market. Under current inventory standards, the market value requires consideration of replacement cost, net realizable value and net realizable value less an approximately normal profit margin. The new guidance replaces market with net realizable value defined as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This eliminates the need to determine and consider replacement cost or net realizable value less an approximately normal profit margin when measuring inventory. The standard is required to be adopted for annual periods beginning after December 15, 2016, including interim periods within that annual period. The amendment is to be applied prospectively with early adoption permitted. The Company is in the process of evaluating the effect of the new guidance on its condensed consolidated financial statements and disclosures.   In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under ASU 2016-02, lessees will be required to recognize, for all leases of 12 months or more, a liability to make lease payments and a right-of-use asset representing the right to use the underlying asset for the lease term. Additionally, the guidance requires improved disclosures to help users of financial statements better understand the nature of an entitys leasing activities. This ASU is effective for public reporting companies for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective approach. The Company is in the process of evaluating the effect of the new guidance on its condensed consolidated financial statements and disclosures.   In April 2016, the FASB issued ASU No. 2016-09, Compensation Stock Compensation (topic 718). The FASB issued this update to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The updated guidance is effective for annual periods beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company is currently evaluating the impact of the new standard.   In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing (topic 606). In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross verses Net) (topic 606). These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, Revenue from Contracts with Customers. The amendments in ASU 2016-10 provide clarifying guidance on materiality of performance obligations; evaluating distinct performance obligations; treatment of shipping and handling costs; and determining whether an entity's promise to grant a license provides a customer with either a right to use an entity's intellectual property or a right to access an entity's intellectual property. The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The adoption of ASU 2016-10 and ASU 2016-08 is to coincide with an entity's adoption of ASU 2014-09, which we intend to adopt for interim and annual reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact of the new standard.   In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which narrowly amended the revenue recognition guidance regarding collectability, noncash consideration, presentation of sales tax and transition and is effective during the same period as ASU 2014-09. The Company is currently evaluating the impact of the new standard.   In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU 2016-15). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017. The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently in the process of evaluating the impact of ASU 2016-15 on its consolidated financial statements.   Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying consolidated financial statements.

3.             PROPERTY AND EQUIPMENT   Property and equipment on September 30, 2016 and December 31, 2015 are as follows:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="81%" style='width:81.06%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='padding:0'>   </td> <td valign="bottom" style='padding:0'>   </td> <td width="18%" colspan="2" valign="bottom" style='width:18.14%;border:none;border-bottom:solid black 1.5pt;padding:0'> September 30, 2016 </td> <td valign="bottom" style='padding:0'>   </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> December 31, 2015 </td> <td valign="bottom" style='padding:0'>   </td> </tr> <tr align="left"> <td width="57%" valign="bottom" style='width:57.22%;background:#CCEEFF;padding:0'> Machinery and Equipment </td> <td width="1%" valign="bottom" style='width:1.94%;background:#CCEEFF;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.08%;background:#CCEEFF;padding:0'> $ </td> <td width="17%" valign="bottom" style='width:17.08%;background:#CCEEFF;padding:0'> 775,422 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCEEFF;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.94%;background:#CCEEFF;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.08%;background:#CCEEFF;padding:0'> $ </td> <td width="17%" valign="bottom" style='width:17.74%;background:#CCEEFF;padding:0'> 175,583 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCEEFF;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td width="17%" valign="bottom" style='width:17.08%;background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:#CCEEFF;padding:0in 0in 1.5pt 0in'> Less: Accumulated Depreciation </td> <td valign="bottom" style='background:#CCEEFF;padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:#CCEEFF;padding:0'>   </td> <td width="17%" valign="bottom" style='width:17.08%;border:none;border-bottom:solid black 1.5pt;background:#CCEEFF;padding:0'> 90,158 </td> <td valign="bottom" style='background:#CCEEFF;padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='background:#CCEEFF;padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:#CCEEFF;padding:0'>   </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:#CCEEFF;padding:0'> 2,790 </td> <td valign="bottom" style='background:#CCEEFF;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td width="17%" valign="bottom" style='width:17.08%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> 685,264 </td> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> 172,793 </td> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'>   </td> </tr> </table> </div>   Depreciation expense charged to income for the nine months ended September 30, 2016 and 2015 amounted to $87,368 and $0, respectively. Depreciation expense charged to income for the three months ended September 30, 2016 and 2015 amounted to $38,383 and $0, respectively.

4.             INVESTMENT IN NON-PUBLICLY TRADED COMPANY   During the fourth quarter of 2015, the Company issued convertible promissory notes to an accredited investor for an aggregate total of 60,000 shares of stock in a non-publicly traded company which it valued at $720,000 based on the subsequent sale of a portion of those shares during the period for $12 per share. The Company sold 20,000 and 40,000 shares in November 2015 and February 2016, respectively, for approximately $240,000 and $480,000, respectively, resulting in a reduction of the investment. As of September 30, 2016, the balance of the investment was $0.   The following table summarizes the activity for the investment in non-publicly traded company:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="498" valign="bottom" style='width:373.85pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="118" colspan="2" valign="bottom" style='width:88.85pt;border:none;border-bottom:solid black 1.0pt;padding:0'> September 30, 2016 </td> </tr> <tr align="left"> <td width="498" valign="bottom" style='width:373.85pt;background:#CCEEFF;padding:0'> Balance at January 1, 2016 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> <td width="7" valign="bottom" style='width:5.25pt;background:#CCEEFF;padding:0'> $ </td> <td width="111" valign="bottom" style='width:83.6pt;background:#CCEEFF;padding:0'> 480,000 </td> </tr> <tr align="left"> <td width="498" valign="bottom" style='width:373.85pt;background:white;padding:0'> Additions stock of non-publicly traded company </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0'>   </td> <td width="7" valign="bottom" style='width:5.25pt;background:white;padding:0'>   </td> <td width="111" valign="bottom" style='width:83.6pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td width="498" valign="bottom" style='width:373.85pt;background:#CCEEFF;padding:0in 0in 1.5pt 0in'> Disposal sale of stock of non-publicly traded company </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 1.5pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.25pt;border:none;border-bottom:solid black 1.0pt;background:#CCEEFF;padding:0'>   </td> <td width="111" valign="bottom" style='width:83.6pt;border:none;border-bottom:solid black 1.0pt;background:#CCEEFF;padding:0'> (480,000) </td> </tr> <tr align="left"> <td width="498" valign="bottom" style='width:373.85pt;background:white;padding:0in 0in 3.0pt 0in'> Balance at September 30, 2016 </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.25pt;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td width="111" valign="bottom" style='width:83.6pt;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> </tr> </table> </div>

5.             CONVERTIBLE NOTES PAYABLE   In April 2013, the Company borrowed $100,000 in exchange for a 4% convertible promissory note due April 30, 2015 and a five-year warrant to purchase 50,000 shares of common stock at $2 each. The note is convertible at any time prior to maturity at the option of the holder at $2 per share of common stock (50,000 shares). The relative fair value of the warrant issued was $32,525 based on the Black-Scholes option pricing model. The relative fair value of the warrant was recorded as a discount and is being amortized over two years based on the effective interest method. The unamortized discount at September 30, 2016 and December 31, 2015 was $0 and $0, respectively. The note requires interest payments semi-annually. In April 2015, the note and the related warrants were extended for an additional two year period maturing in April 2017. The debt modification was evaluated under ASC 470-50, Debt Modification and Extinguishments. The Company determined that it was appropriate to account for the term extension on a prospective basis and the carrying amount of the debt remained unchanged. All costs incurred with third parties directly related to the maturity extension were expensed as incurred.   During the third and fourth quarters of 2015, the Company borrowed an aggregate of $1,300,000 in exchange for 4% convertible notes (the 4% Convertible Notes) with the following terms: (i) maturing on October 1, 2018 ($300,000) and November 1, 2018 ($1,000,000) (ii) quarterly cash interest due of 4% (iii) convertible into common stock at any time at the holders option at $2.50 per share and (iv) automatically convertible into common stock after May 5, 2017 at $2.50 per share if after that date the common stock trades above that price for 20 trading days with an average daily volume of 25,000 shares. As discussed in Note 8, $1.0 million was borrowed from a related party.   During the fourth quarter of 2015, the Company issued 4% Convertible Notes in the aggregate principal amount of $900,000 in exchange for 60,000 shares of stock in a non-publicly traded company valued at $15 per share (discussed in Note 4). Upon issuance of the notes, a debt discount of $180,000 was recorded for the value of the common shares of the non-publicly traded company and is being amortized using the effective interest method. The amortization of debt discount is included as a component of interest expense in the condensed consolidated statements of operations. There was an aggregate unamortized debt discount of $129,519 and $173,782 as of September 30, 2016 and December 31, 2015, respectively.

6.             FAIR VALUE OF FINANCIAL INSTRUMENTS   The Company follows the provisions of ASC 820 for fair value measurements of its financial assets and liabilities. The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The accounting standard established a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. This hierarchy prioritizes the inputs into three broad levels, as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the Company's own assumptions used to measure assets and liabilities at fair value. An asset or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

7.             COMMITMENTS AND CONTINGENCIES   Operating Lease   In June 2012, the Company entered into an operating lease for its office space for $3,103 per month through June 2015, with a three year renewal option extending to June 2018. The future minimum rental payments to be paid under the non-cancelable operating lease in effect at March 31, 2015 was $9,309. In April 2015, the Company and the landlord agreed to extend and expand that lease agreement by increasing the size of the space rented. The annual rent according to the amended lease is $91,050 per year payable in equal monthly installments of $7,587, plus the Companys share of common area maintenance charges and electricity. The amended lease is subject to a five-year extension at the election of the Company.   Employment Agreement   Mr. Ilan Reich is employed pursuant to an agreement as President, CEO and Chairman of the Company. Additionally, he will serve as Chief Financial Officer until the Board appoints a replacement. The term of his employment is to December 31, 2022 with automatic renewal for 2 year terms unless either party provides written notice. For now, Mr. Reich will not receive a base salary but will receive up to a US$5,000,000 bonus upon the achievement of the Milestone Goals. Milestone Goals shall mean (i) positive Earnings Before Interest Taxes Depreciation and Amortization, or EBITDA, for the Companys last fiscal year, as reflected in the Companys Annual Report on Form 10-K, and (ii) gross revenues of more than $20,000,000 for the Companys last fiscal year, as reflected in the Companys Annual Report on Form 10-K. The bonus will be paid in stock, to Mr. Reich, or in his sole discretion, fully or partially to employees and/or officers of the Company, in such amounts (up to the total amount of the bonus) and to such employees and/or officers as designated by Mr. Reich in writing to the Company. Mr. Reich is reimbursed by the Company up to $105,000 in calendar year 2016 which amount shall be increased by 5% (compounding) in each subsequent calendar year during the term of the Agreement for office, travel, entertainment, insurance (health, automobile or otherwise), automobile and other expenses arising during the term of the agreement. Additionally, Mr. Reich shall be eligible to participate in incentive, stock purchase, savings, retirement (401K) and welfare benefit plans including, without limitation, health, medical, dental, vision, life (including accidental death and dismemberment) and disability insurance plans. The Company cannot terminate Mr. Reichs employment without cause. Mr. Reich may resign on 30 days notice to the Company. Mr. Reich is entitled to payment of the balance of his contract on resignation for death or disability, good reason or following a Change in Control (defined in the agreement as the accumulation by any individual of 10% or more of the shares of the Company whether by merger, consolidation, sale or other transfer). Additionally, the employment agreement provides a non-compete/non-solicitation provision for a 12 month period following the termination of Mr. Reichs employment with the Company.

8.             RELATED PARTY TRANSACTIONS   In December 2014, the Company borrowed an aggregate of $50,000 in exchange for an interest free demand note from a former member of the board of managers. The loan was repaid in January 2015.   In January 2015, the Company borrowed an aggregate of $50,000 in exchange for an interest free demand note from a former member of the board of managers. In addition, the Company issued warrants to purchase 50,000 shares of common stock at $1.00 per share to the lender. The warrants expire in 2020. The relative fair value of the warrant issued was $31,149 based on the Black-Scholes option pricing model. As a result of this transaction, the Company recorded a debt discount and corresponding amortization expense of $31,149. The loan was repaid in January 2015.   In October 2015, the Company sold a 4% Convertible Note in the principal amount of $1,000,000 to a related party. See Note 5.

9.             Stockholders EQUITY (deficit)   The Companys capital structure consists of the authorization to issue 100,000,000 shares of common stock and 20,000,000 shares of Preferred Stock, which may be issued in series as designated by the Board of Directors. Each series of Preferred Stock shall have such voting and other rights as designated at the time of establishment by the Board of Directors.   Each issued share of common stock and Series A Preferred Stock has one vote and the approval of a majority of the Series A Preferred Stock, voting as a separate class, is required to approve any corporate action requiring shareholder approval. The Series A Preferred Stock is entitled to participate in dividends, rights issuances and property distributions on the same terms that the Class B member units had since the formation of the Company; namely, 20% of the dividends, rights and property distributed to common stockholders. Upon liquidation of the Company, the Series A Preferred Stock is entitled to 20% of the liquidation value, subject to a priority $13,470,000 allocation to the common shares. This formulation preserves the right of the former Class B member units to participate in profits once the holders of Class A member units recouped their aggregate capital contributions.   During January 2015, the Company received $611,939 for the payoff of notes originally issued to purchase common stock and all accrued interest.   In January 2015, the Company entered into an equity financing agreement with a third party who committed to raise an aggregate of $1,500,000 by February 28, 2016.  This commitment was satisfied through (a) the sale of an aggregate of 697,000 shares of common stock to accredited investors for proceeds of $1,009,125 (for an average price of $1.45 per share) net of offering costs of $134,750, and (b) the exchange of 4% Convertible Notes for stock of a non-publicly traded company (See Note 4).   During February 2016, the Company raised approximately $4.2 million of cash through the sale of approximately 1.7 million shares of a new class of Preferred Stock designated as Series B Preferred Stock.  The shares of Series B Preferred Stock:   ·         have a stated value of $2.50 and a conversion price of $2.50, subject to certain adjustments;   ·         are convertible into such number of shares of common stock as determined by dividing the number of shares of Series B Preferred Stock being converted, multiplied by the stated value, divided by the conversion price then in effect;   ·         are entitled to one vote for each share of Series B Preferred Stock on any matter submitted to holders of common stock;   ·         are entitled to dividends at the annual rate of 9.5% (which will increase to 12% in the event that by June 30, 2018, the Company does not obtain CE Mark approval of its Therapeutic Oncopheresis System and generate at least $600,000 of gross profit in two fiscal quarters, subject to certain conditions), payable quarterly in shares of Series B Preferred Stock;   ·         upon any liquidation, will be entitled to receive, prior to any payments in respect of the Companys common stock, an amount equal to the stated value plus any accrued but unpaid dividends; and   ·         beginning in 2022, will automatically convert into common stock in the event that the closing price of the common stock is at least $4.00 for 20 consecutive trading days with a minimum average trading volume of at least 25,000 shares for such period.   In conjunction with that financing the terms of the Series A Preferred Stock were amended to provide that it will not participate in dividends payable in shares of Series B Preferred Stock to the holders of the Series B Preferred Stock, and to provide that the liquidation amount payable to the holders of Series A Preferred Stock will be paid following payment of the liquidation amount due to holders of Series B Preferred Stock.   On April 1, 2016, the Company issued 75,000 shares of common stock to an employee for services rendered. The Company expensed an aggregate $125,625 as stock-based compensation relating to these shares.   During the nine months ended September 30, 2016 and 2015, the Company expensed an aggregate of $2,362,823 and $1,117,015, respectively, included in the condensed consolidated statement of operations for stock based compensation.  This includes the previously mentioned $125,625, the below mentioned $1,888,287 for restricted stock, and the below mentioned $348,911 for warrants.   During the three months ended September 30, 2016 and 2015, the Company expensed an aggregate of $149,528 and $160,266, respectively, included in the condensed consolidated statement of operations for stock based compensation for services provided.   As of September 30, 2016, 4,000,000 shares of Series A Preferred Stock, 1,733,801 shares of Series B Preferred Stock and 19,495,426 shares of common stock were issued and outstanding.   See Note 2 for a description of potential common stock equivalents.    Restricted Stock                 The Company periodically grants restricted stock awards to certain employees and consultants pursuant to the Companys 2014 Incentive Plan that typically vest one to two years from their grant date. The Company recognized an aggregate of $1,888,287 in compensation expense during the nine months ended September 30, 2016, related to restricted stock awards. Stock compensation expense is recognized over the vesting period of the restricted stock. At September 30, 2016 the Company had approximately $186,898 of total unrecognized compensation cost related to non-vested restricted stock, all of which will be recognized through September 2017.   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Restricted Stock </td> <td colspan="2" valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" colspan="2" valign="top" style='width:.42%;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Weighted Average Exercise Price </td> </tr> <tr style='height:14.25pt'> <td style='padding:0;height:14.25pt'>   </td> <td colspan="2" style='padding:0;height:14.25pt'>   </td> <td colspan="2" style='padding:0;height:14.25pt'>   </td> <td width="0%" colspan="2" valign="top" style='width:.42%;padding:0;height:14.25pt'>   </td> <td width="0%" style='width:.72%;padding:0;height:14.25pt'>   </td> <td colspan="2" style='padding:0;height:14.25pt'>   </td> </tr> <tr align="left"> <td style='background:white;padding:0'> Non-vested December 31, 2015 </td> <td style='background:white;padding:0'>   </td> <td style='background:white;padding:0'> 470,167 </td> <td width="0%" style='width:.68%;background:white;padding:0'>   </td> <td width="0%" colspan="2" valign="top" style='width:.32%;background:white;padding:0'>   </td> <td colspan="2" style='background:white;padding:0'>   </td> <td style='background:white;padding:0'> $ </td> <td style='background:white;padding:0'> 1.72 </td> </tr> <tr align="left"> <td style='background:white;padding:0'> Granted </td> <td style='background:white;padding:0'>   </td> <td style='background:white;padding:0'> 960,000 </td> <td width="0%" style='width:.68%;background:white;padding:0'>   </td> <td width="0%" colspan="2" valign="top" style='width:.32%;background:white;padding:0'>   </td> <td colspan="2" style='background:white;padding:0'>   </td> <td style='background:white;padding:0'> $ </td> <td style='background:white;padding:0'> 1.68 </td> </tr> <tr align="left"> <td style='background:#CCEEFF;padding:0'> Vested </td> <td style='background:#CCEEFF;padding:0'>   </td> <td style='background:#CCEEFF;padding:0'> (1,064,333) </td> <td width="0%" style='width:.68%;background:#CCEEFF;padding:0'></td> <td width="0%" colspan="2" valign="top" style='width:.32%;background:#CCEEFF;padding:0'>   </td> <td colspan="2" style='background:#CCEEFF;padding:0'>   </td> <td style='background:#CCEEFF;padding:0'> $ </td> <td style='background:#CCEEFF;padding:0'> 1.69 </td> </tr> <tr align="left"> <td style='background:white;padding:0in 0in 1.5pt 0in'> Forfeited/Cancelled </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="0%" style='width:.68%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" colspan="2" valign="top" style='width:.32%;background:white;padding:0'>   </td> <td colspan="2" style='background:white;padding:0in 0in 1.5pt 0in'>   </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td style='background:white;padding:0in 0in 2.5pt 0in'> Non-vested September 30, 2016 </td> <td style='border:none;border-bottom:double black 1.5pt;background:white;padding:0'>   </td> <td style='border:none;border-bottom:double black 1.5pt;background:white;padding:0'> 365,834 </td> <td width="0%" style='width:.68%;background:white;padding:0in 0in 2.5pt 0in'>   </td> <td width="0%" colspan="2" valign="top" style='width:.32%;background:white;padding:0'>   </td> <td colspan="2" style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td style='border:none;border-bottom:double black 1.5pt;background:white;padding:0'> $ </td> <td style='border:none;border-bottom:double black 1.5pt;background:white;padding:0'> 1.70 </td> </tr> <tr align="left"> <td width="303" style='border:none'></td> <td width="7" style='border:none'></td> <td width="142" style='border:none'></td> <td width="4" style='border:none'></td> <td width="1" style='border:none'></td> <td width="1" style='border:none'></td> <td width="3" style='border:none'></td> <td width="4" style='border:none'></td> <td width="30" style='border:none'></td> <td width="104" style='border:none'></td> </tr> </table> </div>   The following is a summary of the Companys warrant activity:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="79%" style='width:79.22%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>    </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Warrants </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Weighted Average Exercise Price </td> </tr> <tr align="left"> <td style='padding:0'>   </td> <td colspan="2" style='padding:0'>   </td> <td style='padding:0'>   </td> <td style='padding:0'>   </td> <td colspan="2" style='padding:0'>   </td> </tr> <tr align="left"> <td style='background:white;padding:0'> Outstanding January 1, 2016 </td> <td style='background:white;padding:0'>   </td> <td valign="top" style='background:white;padding:0'> 535,000 </td> <td valign="top" style='background:white;padding:0'>   </td> <td valign="top" style='background:white;padding:0'>   </td> <td valign="top" style='background:white;padding:0'> $ </td> <td valign="top" style='background:white;padding:0'> 1.42 </td> </tr> <tr align="left"> <td style='background:#CCEEFF;padding:0'> Exercisable January 1, 2016 </td> <td style='background:#CCEEFF;padding:0'>   </td> <td valign="top" style='background:#CCEEFF;padding:0'> 535,000 </td> <td valign="top" style='background:#CCEEFF;padding:0'>   </td> <td valign="top" style='background:#CCEEFF;padding:0'>   </td> <td valign="top" style='background:#CCEEFF;padding:0'> $ </td> <td valign="top" style='background:#CCEEFF;padding:0'> 1.42 </td> </tr> <tr align="left"> <td style='background:white;padding:0'> Granted </td> <td style='background:white;padding:0'>   </td> <td style='background:white;padding:0'> 417,981 </td> <td style='background:white;padding:0'>   </td> <td style='background:white;padding:0'>   </td> <td style='background:white;padding:0'> $ </td> <td style='background:white;padding:0'> 1.50 </td> </tr> <tr align="left"> <td style='background:#CCEEFF;padding:0'> Exercised </td> <td style='background:#CCEEFF;padding:0'>   </td> <td style='background:#CCEEFF;padding:0'> - </td> <td style='background:#CCEEFF;padding:0'></td> <td style='background:#CCEEFF;padding:0'>   </td> <td style='background:#CCEEFF;padding:0'> $ </td> <td style='background:#CCEEFF;padding:0'> - </td> </tr> <tr align="left"> <td style='background:white;padding:0in 0in 1.5pt 0in'> Forfeited/Cancelled </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> (175,000) </td> <td style='background:white;padding:0in 0in 1.5pt 0in'>   </td> <td style='background:white;padding:0in 0in 1.5pt 0in'>   </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td style='background:white;padding:0in 0in 2.5pt 0in'> Outstanding September 30, 2016 </td> <td style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'>   </td> <td style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> 777,981 </td> <td style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> 1.42 </td> </tr> <tr align="left"> <td style='background:#CCEEFF;padding:0in 0in 2.5pt 0in'> Exercisable September 30, 2016 </td> <td style='border:none;border-bottom:double black 2.25pt;background:#CCEEFF;padding:0'>   </td> <td style='border:none;border-bottom:double black 2.25pt;background:#CCEEFF;padding:0'> 777,981 </td> <td style='background:#CCEEFF;padding:0in 0in 2.5pt 0in'>   </td> <td style='background:#CCEEFF;padding:0in 0in 2.5pt 0in'>   </td> <td style='border:none;border-bottom:double black 2.25pt;background:#CCEEFF;padding:0'> $ </td> <td style='border:none;border-bottom:double black 2.25pt;background:#CCEEFF;padding:0'> 1.42 </td> </tr> </table> </div>     <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td colspan="11" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Warrants Outstanding </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="5" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Warrants Exercisable </td> </tr> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Range of Exercise Price </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Number Outstanding </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Weighted Average Remaining Contractual Life (in years) </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Weighted Average Exercise Price </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Number Exercisable </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Weighted Average Exercise Price </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="14%" valign="bottom" style='width:14.98%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.98%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="13%" valign="bottom" style='width:13.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.98%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.98%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.98%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.08%;background:white;padding:0'>   </td> <td width="13%" valign="bottom" style='width:13.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.98%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.98%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.98%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.08%;background:white;padding:0'>   </td> <td width="13%" valign="bottom" style='width:13.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:#CCEEFF;padding:0'> $1.00-$2.00 </td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'> 777,981 </td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'> 3.67 years </td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'> $ </td> <td valign="bottom" style='background:#CCEEFF;padding:0'> 1.42 </td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'> 777,981 </td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'> $ </td> <td valign="bottom" style='background:#CCEEFF;padding:0'> 1.42 </td> <td valign="bottom" style='background:#CCEEFF;padding:0'>   </td> </tr> </table>   The following table summarizes the assumptions the Company utilized to estimate the fair value of the convertible note and warrants, and derivative liability issued during the nine months ended September 30, 2016:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="280" style='width:210.0pt;border-collapse:collapse'> <tr align="left"> <td width="136" valign="top" style='width:101.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Assumptions </td> <td width="18" valign="top" style='width:13.15pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="127" valign="top" style='width:95.05pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> September 30, 2016 </td> </tr> <tr align="left"> <td width="136" valign="top" style='width:101.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="18" valign="top" style='width:13.15pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="127" valign="top" style='width:95.05pt;border:none;padding:0in 5.4pt 0in 5.4pt'>   </td> </tr> <tr align="left"> <td width="136" valign="top" style='width:101.8pt;padding:0in 5.4pt 0in 5.4pt'> Expected term (years) </td> <td width="18" valign="top" style='width:13.15pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="127" valign="top" style='width:95.05pt;padding:0in 5.4pt 0in 5.4pt'> 5.00 </td> </tr> <tr align="left"> <td width="136" valign="top" style='width:101.8pt;padding:0in 5.4pt 0in 5.4pt'> Expected volatility </td> <td width="18" valign="top" style='width:13.15pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="127" valign="top" style='width:95.05pt;padding:0in 5.4pt 0in 5.4pt'> 86.6% </td> </tr> <tr align="left"> <td width="136" valign="top" style='width:101.8pt;padding:0in 5.4pt 0in 5.4pt'> Risk-free interest rate </td> <td width="18" valign="top" style='width:13.15pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="127" valign="top" style='width:95.05pt;padding:0in 5.4pt 0in 5.4pt'> 1.24% </td> </tr> <tr align="left"> <td width="136" valign="top" style='width:101.8pt;padding:0in 5.4pt 0in 5.4pt'> Dividend yield </td> <td width="18" valign="top" style='width:13.15pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="127" valign="top" style='width:95.05pt;padding:0in 5.4pt 0in 5.4pt'> 0.00% </td> </tr> </table> </div>   The expected warrant term is based on the remaining contractual term. The expected volatility is based on historical-volatility of peer entities whose stock prices were publicly available. The risk-free interest rate is based on the U.S. Treasury yields with terms equivalent to the expected term of the related warrant at the valuation date. Dividend yield is based on historical trends.   During the nine months ended September 30, 2016, the Company issued warrants for advisory services and expensed an aggregate of $348,911 as stock based compensation.

10. SUBSEQUENT EVENTS   In October 2016, the Company borrowed $300,000 from the President and CEO of the Company pursuant to an interest-free demand note.

Basis of Accounting   The accompanying unaudited condensed consolidated financial statements have been prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (GAAP).   The financial statements contained herein have been prepared by the Company in accordance with GAAP for interim financial information. Accordingly, they do not include all information and footnotes required by GAAP for complete financial statements. The balance sheet at December 31, 2015 was derived from audited financial statements but does not include all disclosures required by GAAP. In the opinion of management, the interim financial statements include all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of the results of the periods presented. The results of operations for the nine and three months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto for the year ended December 31, 2015.

Principles of Consolidation   The accompanying condensed consolidated financial statements include the accounts of Viatar CTC Solutions Inc., the Subsidiary and amounts related to a noncontrolling interest in the Subsidiary. The noncontrolling interest represents a 0.001% ownership interest in the Subsidiary at September 30, 2016 and December 31, 2015. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Significant estimates subject to such estimates and assumptions include the valuation of debt and equity instruments issued for services and in connection with agreements and contracts entered in to by the Company. Actual results could differ from those estimates.

Cash   The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents. The Company held no cash equivalents at September 30, 2016 or December 31, 2015.   The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits.

Fair Value of Financial Instruments   The Companys financial instruments consist of cash, accounts payable and accrued expenses. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of September 30, 2016 and December 31, 2015, the carrying amount of cash, accounts payable and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.

Property and Equipment   Property and equipment are recorded at cost. Depreciation expense is computed using straight-line methods over the estimated useful lives.   Asset lives for financial statement reporting of depreciation are:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr align="left"> <td width="60%" valign="top" style='width:60.0%;padding:0'> Machinery and equipment </td> <td width="2%" valign="top" style='width:2.0%;padding:0'>   </td> <td width="38%" valign="top" style='width:38.0%;padding:0'> 5 years </td> </tr> </table> </div>

Cost-Method Investment   The Companys cost-method investment in a non-publicly traded company is included in the condensed consolidated balance sheets and is carried at cost, adjusted for any impairment, because the Company does not have a controlling interest and does not have the ability to exercise significant influence over this company. The Company monitors any such investment for impairment on a quarterly basis, and adjusts carrying value for any impairment charges recognized. Realized gains and losses on this investment are reported in other income (expense), net in the condensed consolidated statements of operations.   As of September 30, 2016 the Company does not have any investment in any non-publicly traded company. See Note 4.

Revenue Recognition   The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the product is delivered, (3) the sales price to the customer is fixed or determinable, and (4) collectability of the related customer receivable is reasonably assured. There is no stated right of return for products. The Company generally meets these criteria upon shipment.

Cost of Sales   Cost of sales represents costs directly related to the production and manufacturing of the Companys products for commercial sale to customers. Costs include product cost, freight, packaging, and labor costs.

Research and Development   Research and development costs consist of ongoing testing (including pre-clinical and clinical), research and development, and are expensed as incurred.

Derivatives   The Company evaluated its options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, Derivatives and Hedging. The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassed to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liability at the fair value of the instrument on the reclassification date.

Income Taxes   In the ordinary course of business, there is inherent uncertainty in quantifying income tax positions. The Company assesses its income tax positions and records tax assets or liabilities for all years subject to examination based upon managements evaluation of the facts and circumstances and information available at the reporting dates. For those tax positions where it is more-likely-than-not that a tax benefit will be sustained, we have recorded the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more-likely-than-not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. The Company records interest and penalties related to uncertain tax positions as a component of income tax expense or benefit.   The Company files income tax returns with the U.S. federal government and various state and local jurisdictions. The Company is no longer subject to tax examinations by tax authorities for years prior to 2012.   The Company is currently under audit by New York City tax authorities for the 2011, 2012, and 2013 tax years. The Company applied for New York City biotechnology tax credits and received certificates of eligibility from the NYC Department of Finance in the amounts of $147,997, $242,016, and $236,874 for tax years 2013, 2012, and 2011, respectively. The Company received refunds for these amounts in previous years. The City of New York subsequently ruled that the Company does not qualify for the tax credits. As of September 30, 2016, the Company accrued $626,887 on the condensed consolidated balance sheets, as well as $194,955 of interest at the statutory rate, which is included in accounts payable and accrued expenses on the condensed consolidated balance sheets. The Company appealed the decision made by the City of New York. While settlement discussions have been held, as of the date of this report no decision has been made regarding the appeal or settlement.

Commitments and Contingencies   The Company follows subtopic 450-20 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) to report accounting for contingencies. Certain conditions may exist as of the date the condensed consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.    If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Companys condensed consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.   Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

Stock-Based Compensation   In December 2004, the FASB issued ASC 718, Compensation Stock Compensation, or ASC 718. Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. The Company amortizes such compensation amounts, if any, over the respective vesting periods of the award. The Company uses the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, that requires the input of highly complex and subjective variables, including the expected life of the award and the expected stock price volatility over a period equal to or greater than the expected life of the award.   Equity instruments (Instruments) issued to anyone other than employees are recorded on the basis of the fair value of the Instruments, as required by ASC 718. ASC 505, Equity Based Payments to Non-Employees, or ASC 505, defines the measurement date and recognition period for such Instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the Instruments are vested. The measured value related to the Instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.   The Company recognizes the compensation expense for all share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. The Company generally recognizes the compensation expense on a straight-line basis over the employees requisite service period.

Earnings (Loss) Per Share   Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss), adjusted for changes in income or loss that resulted from the assumed conversion of convertible shares, by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period.   The Company had the following potential common stock equivalents as of September 30, 2016 and 2015:     <table border="0" cellspacing="0" cellpadding="0" width="595" style='margin-left:.5in;border-collapse:collapse'> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;padding:0in 0in 1.5pt 0in'> As of </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="11" valign="bottom" style='width:8.3pt;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;padding:0'> September 30, 2016 </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="70" valign="bottom" style='width:52.6pt;padding:0'> September 30, 2015 </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;padding:0in 0in 1.5pt 0in'> Common stock warrants, exercise price range of $1.00-$2.00 </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="11" valign="bottom" style='width:8.3pt;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;padding:0'> 777,981 </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="70" valign="bottom" style='width:52.6pt;padding:0'> - </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;background:#CCEEFF;padding:0'> Conversion feature on convertible notes, exercise price of $2.50 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> <td width="11" valign="bottom" style='width:8.3pt;background:#CCEEFF;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;background:#CCEEFF;padding:0'> 920,000 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> <td width="70" valign="bottom" style='width:52.6pt;background:#CCEEFF;padding:0'> 120,000 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> </tr> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;background:white;padding:0in 0in 1.5pt 0in'> Conversion feature on Series B preferred stock, exercise price of $2.50 </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="11" valign="bottom" style='width:8.3pt;background:white;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:white;padding:0'> 1,733,801 </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="70" valign="bottom" style='width:52.6pt;border:none;border-bottom:solid windowtext 1.0pt;background:white;padding:0'> 535,000 </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>  Total common stock equivalents </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>   </td> <td width="11" valign="bottom" style='width:8.3pt;background:#CCEEFF;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> 3,431,782 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>   </td> <td width="70" valign="bottom" style='width:52.6pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> 655,000 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>   </td> </tr> </table>   Since the Company reflected a net loss during the nine and three months ended September 30, 2016 and 2015, the effect of considering any common stock equivalents would have been anti-dilutive. Therefore, a separate computation of diluted earnings (loss) per share is not presented.

Reclassification   Certain prior period amounts have been reclassified to conform to current period presentation. The reclassifications did not have an impact on net loss as previously reported.

Recent Accounting Pronouncements   In May 2014, the FASB issued a comprehensive new revenue recognition standard that will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standards core principle (issued as ASU 2014-09 by the FASB), is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The new guidance must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. In August 2015, the FASB issued ASU No. 2015-14, which defers the effective date of ASU 2014-09 by one year, and would allow entities the option to early adopt the new revenue standard as of the original effective date. This ASU is effective for public reporting companies for interim and annual periods beginning after December 15, 2017. The Company is currently evaluating its adoption method and the impact of the standard on its condensed consolidated financial statements.   In March 2015, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption of the amendments is permitted for financial statements that have not been previously issued. The amendments should be applied on a retrospective basis, wherein the balance sheet of each individual period presented should be adjusted to reflect the period-specific effects of applying the new guidance. Upon transition, an entity is required to comply with the applicable disclosures for a change in an accounting principle. These disclosures include the nature of and reason for the change in accounting principle, the transition method, a description of the prior-period information that has been retrospectively adjusted, and the effect of the change on the financial statement line items (i.e., debt issuance cost asset and the debt liability). The Company adopted ASU 2015-03 during the period ended September 30, 2016.   In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, which modifies existing requirements regarding measuring inventory at the lower of cost or market. Under current inventory standards, the market value requires consideration of replacement cost, net realizable value and net realizable value less an approximately normal profit margin. The new guidance replaces market with net realizable value defined as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This eliminates the need to determine and consider replacement cost or net realizable value less an approximately normal profit margin when measuring inventory. The standard is required to be adopted for annual periods beginning after December 15, 2016, including interim periods within that annual period. The amendment is to be applied prospectively with early adoption permitted. The Company is in the process of evaluating the effect of the new guidance on its condensed consolidated financial statements and disclosures.   In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Under ASU 2016-02, lessees will be required to recognize, for all leases of 12 months or more, a liability to make lease payments and a right-of-use asset representing the right to use the underlying asset for the lease term. Additionally, the guidance requires improved disclosures to help users of financial statements better understand the nature of an entitys leasing activities. This ASU is effective for public reporting companies for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective approach. The Company is in the process of evaluating the effect of the new guidance on its condensed consolidated financial statements and disclosures.   In April 2016, the FASB issued ASU No. 2016-09, Compensation Stock Compensation (topic 718). The FASB issued this update to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The updated guidance is effective for annual periods beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company is currently evaluating the impact of the new standard.   In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing (topic 606). In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross verses Net) (topic 606). These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, Revenue from Contracts with Customers. The amendments in ASU 2016-10 provide clarifying guidance on materiality of performance obligations; evaluating distinct performance obligations; treatment of shipping and handling costs; and determining whether an entity's promise to grant a license provides a customer with either a right to use an entity's intellectual property or a right to access an entity's intellectual property. The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The adoption of ASU 2016-10 and ASU 2016-08 is to coincide with an entity's adoption of ASU 2014-09, which we intend to adopt for interim and annual reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact of the new standard.   In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which narrowly amended the revenue recognition guidance regarding collectability, noncash consideration, presentation of sales tax and transition and is effective during the same period as ASU 2014-09. The Company is currently evaluating the impact of the new standard.   In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU 2016-15). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017. The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently in the process of evaluating the impact of ASU 2016-15 on its consolidated financial statements.   Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying consolidated financial statements.

<table border="0" cellspacing="0" cellpadding="0" width="595" style='margin-left:.5in;border-collapse:collapse'> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;padding:0in 0in 1.5pt 0in'> As of </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="11" valign="bottom" style='width:8.3pt;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;padding:0'> September 30, 2016 </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="70" valign="bottom" style='width:52.6pt;padding:0'> September 30, 2015 </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;padding:0in 0in 1.5pt 0in'> Common stock warrants, exercise price range of $1.00-$2.00 </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="11" valign="bottom" style='width:8.3pt;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;padding:0'> 777,981 </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="70" valign="bottom" style='width:52.6pt;padding:0'> - </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;background:#CCEEFF;padding:0'> Conversion feature on convertible notes, exercise price of $2.50 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> <td width="11" valign="bottom" style='width:8.3pt;background:#CCEEFF;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;background:#CCEEFF;padding:0'> 920,000 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> <td width="70" valign="bottom" style='width:52.6pt;background:#CCEEFF;padding:0'> 120,000 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> </tr> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;background:white;padding:0in 0in 1.5pt 0in'> Conversion feature on Series B preferred stock, exercise price of $2.50 </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="11" valign="bottom" style='width:8.3pt;background:white;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:white;padding:0'> 1,733,801 </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="70" valign="bottom" style='width:52.6pt;border:none;border-bottom:solid windowtext 1.0pt;background:white;padding:0'> 535,000 </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="420" valign="bottom" style='width:315.0pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>  Total common stock equivalents </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>   </td> <td width="11" valign="bottom" style='width:8.3pt;background:#CCEEFF;padding:0'>   </td> <td width="66" valign="bottom" style='width:49.5pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> 3,431,782 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>   </td> <td width="70" valign="bottom" style='width:52.6pt;border:none;border-bottom:double windowtext 1.5pt;background:#CCEEFF;padding:0'> 655,000 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 3.0pt 0in'>   </td> </tr> </table>

<div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="81%" style='width:81.06%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='padding:0'>   </td> <td valign="bottom" style='padding:0'>   </td> <td width="18%" colspan="2" valign="bottom" style='width:18.14%;border:none;border-bottom:solid black 1.5pt;padding:0'> September 30, 2016 </td> <td valign="bottom" style='padding:0'>   </td> <td valign="bottom" style='padding:0'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> December 31, 2015 </td> <td valign="bottom" style='padding:0'>   </td> </tr> <tr align="left"> <td width="57%" valign="bottom" style='width:57.22%;background:#CCEEFF;padding:0'> Machinery and Equipment </td> <td width="1%" valign="bottom" style='width:1.94%;background:#CCEEFF;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.08%;background:#CCEEFF;padding:0'> $ </td> <td width="17%" valign="bottom" style='width:17.08%;background:#CCEEFF;padding:0'> 775,422 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCEEFF;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.94%;background:#CCEEFF;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.08%;background:#CCEEFF;padding:0'> $ </td> <td width="17%" valign="bottom" style='width:17.74%;background:#CCEEFF;padding:0'> 175,583 </td> <td width="0%" valign="bottom" style='width:.96%;background:#CCEEFF;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td width="17%" valign="bottom" style='width:17.08%;background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> <td valign="bottom" style='background:white;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:#CCEEFF;padding:0in 0in 1.5pt 0in'> Less: Accumulated Depreciation </td> <td valign="bottom" style='background:#CCEEFF;padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:#CCEEFF;padding:0'>   </td> <td width="17%" valign="bottom" style='width:17.08%;border:none;border-bottom:solid black 1.5pt;background:#CCEEFF;padding:0'> 90,158 </td> <td valign="bottom" style='background:#CCEEFF;padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='background:#CCEEFF;padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:#CCEEFF;padding:0'>   </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;background:#CCEEFF;padding:0'> 2,790 </td> <td valign="bottom" style='background:#CCEEFF;padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td width="17%" valign="bottom" style='width:17.08%;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> 685,264 </td> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td valign="bottom" style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> 172,793 </td> <td valign="bottom" style='background:white;padding:0in 0in 2.5pt 0in'>   </td> </tr> </table> </div>

<div align="center"> <table border="0" cellspacing="0" cellpadding="0" style='border-collapse:collapse'> <tr align="left"> <td width="498" valign="bottom" style='width:373.85pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.2pt;padding:0in 0in 1.5pt 0in'>   </td> <td width="118" colspan="2" valign="bottom" style='width:88.85pt;border:none;border-bottom:solid black 1.0pt;padding:0'> September 30, 2016 </td> </tr> <tr align="left"> <td width="498" valign="bottom" style='width:373.85pt;background:#CCEEFF;padding:0'> Balance at January 1, 2016 </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0'>   </td> <td width="7" valign="bottom" style='width:5.25pt;background:#CCEEFF;padding:0'> $ </td> <td width="111" valign="bottom" style='width:83.6pt;background:#CCEEFF;padding:0'> 480,000 </td> </tr> <tr align="left"> <td width="498" valign="bottom" style='width:373.85pt;background:white;padding:0'> Additions stock of non-publicly traded company </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0'>   </td> <td width="7" valign="bottom" style='width:5.25pt;background:white;padding:0'>   </td> <td width="111" valign="bottom" style='width:83.6pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td width="498" valign="bottom" style='width:373.85pt;background:#CCEEFF;padding:0in 0in 1.5pt 0in'> Disposal sale of stock of non-publicly traded company </td> <td width="7" valign="bottom" style='width:5.2pt;background:#CCEEFF;padding:0in 0in 1.5pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.25pt;border:none;border-bottom:solid black 1.0pt;background:#CCEEFF;padding:0'>   </td> <td width="111" valign="bottom" style='width:83.6pt;border:none;border-bottom:solid black 1.0pt;background:#CCEEFF;padding:0'> (480,000) </td> </tr> <tr align="left"> <td width="498" valign="bottom" style='width:373.85pt;background:white;padding:0in 0in 3.0pt 0in'> Balance at September 30, 2016 </td> <td width="7" valign="bottom" style='width:5.2pt;background:white;padding:0in 0in 3.0pt 0in'>   </td> <td width="7" valign="bottom" style='width:5.25pt;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td width="111" valign="bottom" style='width:83.6pt;border:none;border-bottom:double black 2.25pt;background:white;padding:0'> - </td> </tr> </table> </div>   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80.0%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Restricted Stock </td> <td colspan="2" valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" colspan="2" valign="top" style='width:.42%;padding:0'>   </td> <td width="0%" valign="bottom" style='width:.72%;padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Weighted Average Exercise Price </td> </tr> <tr style='height:14.25pt'> <td style='padding:0;height:14.25pt'>   </td> <td colspan="2" style='padding:0;height:14.25pt'>   </td> <td colspan="2" style='padding:0;height:14.25pt'>   </td> <td width="0%" colspan="2" valign="top" style='width:.42%;padding:0;height:14.25pt'>   </td> <td width="0%" style='width:.72%;padding:0;height:14.25pt'>   </td> <td colspan="2" style='padding:0;height:14.25pt'>   </td> </tr> <tr align="left"> <td style='background:white;padding:0'> Non-vested December 31, 2015 </td> <td style='background:white;padding:0'>   </td> <td style='background:white;padding:0'> 470,167 </td> <td width="0%" style='width:.68%;background:white;padding:0'>   </td> <td width="0%" colspan="2" valign="top" style='width:.32%;background:white;padding:0'>   </td> <td colspan="2" style='background:white;padding:0'>   </td> <td style='background:white;padding:0'> $ </td> <td style='background:white;padding:0'> 1.72 </td> </tr> <tr align="left"> <td style='background:white;padding:0'> Granted </td> <td style='background:white;padding:0'>   </td> <td style='background:white;padding:0'> 960,000 </td> <td width="0%" style='width:.68%;background:white;padding:0'>   </td> <td width="0%" colspan="2" valign="top" style='width:.32%;background:white;padding:0'>   </td> <td colspan="2" style='background:white;padding:0'>   </td> <td style='background:white;padding:0'> $ </td> <td style='background:white;padding:0'> 1.68 </td> </tr> <tr align="left"> <td style='background:#CCEEFF;padding:0'> Vested </td> <td style='background:#CCEEFF;padding:0'>   </td> <td style='background:#CCEEFF;padding:0'> (1,064,333) </td> <td width="0%" style='width:.68%;background:#CCEEFF;padding:0'></td> <td width="0%" colspan="2" valign="top" style='width:.32%;background:#CCEEFF;padding:0'>   </td> <td colspan="2" style='background:#CCEEFF;padding:0'>   </td> <td style='background:#CCEEFF;padding:0'> $ </td> <td style='background:#CCEEFF;padding:0'> 1.69 </td> </tr> <tr align="left"> <td style='background:white;padding:0in 0in 1.5pt 0in'> Forfeited/Cancelled </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> <td width="0%" style='width:.68%;background:white;padding:0in 0in 1.5pt 0in'>   </td> <td width="0%" colspan="2" valign="top" style='width:.32%;background:white;padding:0'>   </td> <td colspan="2" style='background:white;padding:0in 0in 1.5pt 0in'>   </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td style='background:white;padding:0in 0in 2.5pt 0in'> Non-vested September 30, 2016 </td> <td style='border:none;border-bottom:double black 1.5pt;background:white;padding:0'>   </td> <td style='border:none;border-bottom:double black 1.5pt;background:white;padding:0'> 365,834 </td> <td width="0%" style='width:.68%;background:white;padding:0in 0in 2.5pt 0in'>   </td> <td width="0%" colspan="2" valign="top" style='width:.32%;background:white;padding:0'>   </td> <td colspan="2" style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td style='border:none;border-bottom:double black 1.5pt;background:white;padding:0'> $ </td> <td style='border:none;border-bottom:double black 1.5pt;background:white;padding:0'> 1.70 </td> </tr> <tr align="left"> <td width="303" style='border:none'></td> <td width="7" style='border:none'></td> <td width="142" style='border:none'></td> <td width="4" style='border:none'></td> <td width="1" style='border:none'></td> <td width="1" style='border:none'></td> <td width="3" style='border:none'></td> <td width="4" style='border:none'></td> <td width="30" style='border:none'></td> <td width="104" style='border:none'></td> </tr> </table> </div>   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="79%" style='width:79.22%;border-collapse:collapse'> <tr align="left"> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>    </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Warrants </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Weighted Average Exercise Price </td> </tr> <tr align="left"> <td style='padding:0'>   </td> <td colspan="2" style='padding:0'>   </td> <td style='padding:0'>   </td> <td style='padding:0'>   </td> <td colspan="2" style='padding:0'>   </td> </tr> <tr align="left"> <td style='background:white;padding:0'> Outstanding January 1, 2016 </td> <td style='background:white;padding:0'>   </td> <td valign="top" style='background:white;padding:0'> 535,000 </td> <td valign="top" style='background:white;padding:0'>   </td> <td valign="top" style='background:white;padding:0'>   </td> <td valign="top" style='background:white;padding:0'> $ </td> <td valign="top" style='background:white;padding:0'> 1.42 </td> </tr> <tr align="left"> <td style='background:#CCEEFF;padding:0'> Exercisable January 1, 2016 </td> <td style='background:#CCEEFF;padding:0'>   </td> <td valign="top" style='background:#CCEEFF;padding:0'> 535,000 </td> <td valign="top" style='background:#CCEEFF;padding:0'>   </td> <td valign="top" style='background:#CCEEFF;padding:0'>   </td> <td valign="top" style='background:#CCEEFF;padding:0'> $ </td> <td valign="top" style='background:#CCEEFF;padding:0'> 1.42 </td> </tr> <tr align="left"> <td style='background:white;padding:0'> Granted </td> <td style='background:white;padding:0'>   </td> <td style='background:white;padding:0'> 417,981 </td> <td style='background:white;padding:0'>   </td> <td style='background:white;padding:0'>   </td> <td style='background:white;padding:0'> $ </td> <td style='background:white;padding:0'> 1.50 </td> </tr> <tr align="left"> <td style='background:#CCEEFF;padding:0'> Exercised </td> <td style='background:#CCEEFF;padding:0'>   </td> <td style='background:#CCEEFF;padding:0'> - </td> <td style='background:#CCEEFF;padding:0'></td> <td style='background:#CCEEFF;padding:0'>   </td> <td style='background:#CCEEFF;padding:0'> $ </td> <td style='background:#CCEEFF;padding:0'> - </td> </tr> <tr align="left"> <td style='background:white;padding:0in 0in 1.5pt 0in'> Forfeited/Cancelled </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'>   </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> (175,000) </td> <td style='background:white;padding:0in 0in 1.5pt 0in'>   </td> <td style='background:white;padding:0in 0in 1.5pt 0in'>   </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> $ </td> <td style='border:none;border-bottom:solid black 1.5pt;background:white;padding:0'> - </td> </tr> <tr align="left"> <td style='background:white;padding:0in 0in 2.5pt 0in'> Outstanding September 30, 2016 </td> <td style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'>   </td> <td style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> 777,981 </td> <td style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td style='background:white;padding:0in 0in 2.5pt 0in'>   </td> <td style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> $ </td> <td style='border:none;border-bottom:double black 2.25pt;background:white;padding:0'> 1.42 </td> </tr> <tr align="left"> <td style='background:#CCEEFF;padding:0in 0in 2.5pt 0in'> Exercisable September 30, 2016 </td> <td style='border:none;border-bottom:double black 2.25pt;background:#CCEEFF;padding:0'>   </td> <td style='border:none;border-bottom:double black 2.25pt;background:#CCEEFF;padding:0'> 777,981 </td> <td style='background:#CCEEFF;padding:0in 0in 2.5pt 0in'>   </td> <td style='background:#CCEEFF;padding:0in 0in 2.5pt 0in'>   </td> <td style='border:none;border-bottom:double black 2.25pt;background:#CCEEFF;padding:0'> $ </td> <td style='border:none;border-bottom:double black 2.25pt;background:#CCEEFF;padding:0'> 1.42 </td> </tr> </table> </div>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100.0%;border-collapse:collapse'> <tr align="left"> <td colspan="11" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Warrants Outstanding </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="5" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Warrants Exercisable </td> </tr> <tr align="left"> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Range of Exercise Price </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Number Outstanding </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Weighted Average Remaining Contractual Life (in years) </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Weighted Average Exercise Price </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Number Exercisable </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> <td colspan="2" valign="bottom" style='border:none;border-bottom:solid black 1.5pt;padding:0'> Weighted Average Exercise Price </td> <td valign="bottom" style='padding:0in 0in 1.5pt 0in'>   </td> </tr> <tr align="left"> <td width="14%" valign="bottom" style='width:14.98%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.98%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="13%" valign="bottom" style='width:13.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.98%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.98%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.98%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.08%;background:white;padding:0'>   </td> <td width="13%" valign="bottom" style='width:13.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.98%;background:white;padding:0'>   </td> <td width="14%" valign="bottom" style='width:14.98%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.98%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.08%;background:white;padding:0'>   </td> <td width="13%" valign="bottom" style='width:13.0%;background:white;padding:0'>   </td> <td width="1%" valign="bottom" style='width:1.0%;background:white;padding:0'>   </td> </tr> <tr align="left"> <td valign="bottom" style='background:#CCEEFF;padding:0'> $1.00-$2.00 </td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'> 777,981 </td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'> 3.67 years </td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'> $ </td> <td valign="bottom" style='background:#CCEEFF;padding:0'> 1.42 </td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'> 777,981 </td> <td valign="bottom" style='background:#CCEEFF;padding:0'></td> <td valign="bottom" style='background:#CCEEFF;padding:0'> $ </td> <td valign="bottom" style='background:#CCEEFF;padding:0'> 1.42 </td> <td valign="bottom" style='background:#CCEEFF;padding:0'>   </td> </tr> </table>

<div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="280" style='width:210.0pt;border-collapse:collapse'> <tr align="left"> <td width="136" valign="top" style='width:101.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> Assumptions </td> <td width="18" valign="top" style='width:13.15pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="127" valign="top" style='width:95.05pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'> September 30, 2016 </td> </tr> <tr align="left"> <td width="136" valign="top" style='width:101.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="18" valign="top" style='width:13.15pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="127" valign="top" style='width:95.05pt;border:none;padding:0in 5.4pt 0in 5.4pt'>   </td> </tr> <tr align="left"> <td width="136" valign="top" style='width:101.8pt;padding:0in 5.4pt 0in 5.4pt'> Expected term (years) </td> <td width="18" valign="top" style='width:13.15pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="127" valign="top" style='width:95.05pt;padding:0in 5.4pt 0in 5.4pt'> 5.00 </td> </tr> <tr align="left"> <td width="136" valign="top" style='width:101.8pt;padding:0in 5.4pt 0in 5.4pt'> Expected volatility </td> <td width="18" valign="top" style='width:13.15pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="127" valign="top" style='width:95.05pt;padding:0in 5.4pt 0in 5.4pt'> 86.6% </td> </tr> <tr align="left"> <td width="136" valign="top" style='width:101.8pt;padding:0in 5.4pt 0in 5.4pt'> Risk-free interest rate </td> <td width="18" valign="top" style='width:13.15pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="127" valign="top" style='width:95.05pt;padding:0in 5.4pt 0in 5.4pt'> 1.24% </td> </tr> <tr align="left"> <td width="136" valign="top" style='width:101.8pt;padding:0in 5.4pt 0in 5.4pt'> Dividend yield </td> <td width="18" valign="top" style='width:13.15pt;padding:0in 5.4pt 0in 5.4pt'>   </td> <td width="127" valign="top" style='width:95.05pt;padding:0in 5.4pt 0in 5.4pt'> 0.00% </td> </tr> </table> </div>

2007-12-18

-6365682

-3957586

-462496 -28822215

21700000

0.0000

777981 920000 120000 1733801 535000 3431782 655000

775422

175583

90158

2790

60000 720000

480000

-480000

100000

0.0400

50000

32525

1300000

0.0400

900000

129519

173782

3103

9309

91050

50000

1.00

31149

100000000

20000000

0.2000

611939

1500000 4000000 1733801

19495426

1888287

186898

470167

1.72

960000

1.68

-1064333

1.69

365834

1.70

535000

1.42

535000

1.42

417981

1.50

-175000

1.00

2.00

777981

P3Y8M1D

1.42

777981

1.42

P5Y

0.8660

0.0124

0.0000

0001616495 2015-12-31 0001616495 2016-01-01 2016-09-30 0001616495 2016-09-30 0001616495 2015-01-01 2015-09-30 0001616495 2016-07-01 2016-09-30 0001616495 2015-07-01 2015-09-30 0001616495 2015-09-30 0001616495 2015-01-01 2015-12-31 0001616495 cik0001616495:ActivityForTheInvestmentsInNonPubliclyTradedCompanyBalanceMember 2016-01-02 0001616495 2016-01-03 2016-09-30 0001616495 us-gaap:ConvertibleNotesPayableMember 2013-04-01 2013-04-30 0001616495 us-gaap:ConvertibleNotesPayableMember 2013-04-30 0001616495 2013-04-30 0001616495 2013-04-01 2013-04-30 0001616495 cik0001616495:ConvertibleNotesPayableThirdQuarterMember 2015-07-01 2015-09-30 0001616495 cik0001616495:ConvertibleNotesPayableThirdQuarterMember 2015-09-30 0001616495 cik0001616495:ConvertibleNotesPayableThirdQuarterMember 2015-12-31 0001616495 cik0001616495:ConvertibleNotesPayableFourthQuarterMember 2015-01-01 2015-12-31 0001616495 cik0001616495:ConvertibleNotesPayableFourthQuarterMember 2016-09-30 0001616495 cik0001616495:ConvertibleNotesPayableFourthQuarterMember 2015-12-31 0001616495 2012-06-01 2012-06-30 0001616495 2015-03-31 0001616495 cik0001616495:RelatedPartyTransactions2014Member 2014-12-31 0001616495 cik0001616495:RelatedPartyTransactions2015Member 2015-01-31 0001616495 cik0001616495:RelatedPartyTransactions2015Member 2015-01-01 2015-01-31 0001616495 2015-01-31 0001616495 2015-01-01 2015-01-31 0001616495 2016-01-02 0001616495 2014-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares pure $0.001 par value, 4,000,000 shares authorized, 4,000,000 shares issued and oustanding at September 30, 2016 and December 31, 2015, respectively. $0.001 par value, 5,000,000 shares authorized, 1,733,801 and 0 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively. $0.001 par value, 11,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively. $0.001 par value, 100,000,000 shares authorized; 19,495,426 and 18,605,426 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively.

EX-101.SCH 3 vrtt-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000160 - Disclosure - 2. Summary of Significant Accounting Policies: Basis of Accounting (Policies) link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - 2. Summary of Significant Accounting Policies: Revenue Recognition (Policies) link:presentationLink link:definitionLink link:calculationLink 000390 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Assumptions Used (Tables) link:presentationLink link:definitionLink link:calculationLink 000310 - Disclosure - 2. Summary of Significant Accounting Policies: Reclassification (Policies) link:presentationLink link:definitionLink link:calculationLink 000330 - Disclosure - 2. Summary of Significant Accounting Policies: Earnings (loss) Per Share: Schedule of Common Stock Equivalents Text Block (Tables) link:presentationLink link:definitionLink link:calculationLink 000530 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Assumptions Used (Details) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - 4. Investment in Non-publicly Traded Company link:presentationLink link:definitionLink link:calculationLink 000320 - Disclosure - 2. Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies) link:presentationLink link:definitionLink link:calculationLink 000460 - Disclosure - 5. Convertible Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 000500 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Non Vested Restricted Stock Text Block (Details) link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - 2. Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - 2. Summary of Significant Accounting Policies: Research and Development (Policies) link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - 10. Subsequent Events link:presentationLink link:definitionLink link:calculationLink 000410 - Disclosure - 2. Summary of Significant Accounting Policies: Principles of Consolidation (Details) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Statement of Financial Position - Parenthetical link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - 2. Summary of Significant Accounting Policies: Cost of Sales (Policies) link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - 2. Summary of Significant Accounting Policies: Principles of Consolidation (Policies) link:presentationLink link:definitionLink link:calculationLink 000470 - Disclosure - 7. Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - 2. Summary of Significant Accounting Policies: Property and Equipment (Policies) link:presentationLink link:definitionLink link:calculationLink 000450 - Disclosure - 4. Investment in Non-publicly Traded Company: Schedule of Investment in Non Publicly Traded Company Text Block (Details) link:presentationLink link:definitionLink link:calculationLink 000370 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Warrant Activity Text Block (Tables) link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - 8. Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - 1. Nature of Operations link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Viatar CTC Solutions, Inc. - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000520 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Stockholders' Equity Note, Warrants or Rights (Details) link:presentationLink link:definitionLink link:calculationLink 000350 - Disclosure - 4. Investment in Non-publicly Traded Company: Schedule of Investment in Non Publicly Traded Company Text Block (Tables) link:presentationLink link:definitionLink link:calculationLink 000270 - Disclosure - 2. Summary of Significant Accounting Policies: Income Taxes (Policies) link:presentationLink link:definitionLink link:calculationLink 000510 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Warrant Activity Text Block (Details) link:presentationLink link:definitionLink link:calculationLink 000280 - Disclosure - 2. Summary of Significant Accounting Policies: Commitments and Contingencies (Policies) link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 000360 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Non Vested Restricted Stock Text Block (Tables) link:presentationLink link:definitionLink link:calculationLink 000290 - Disclosure - 2. Summary of Significant Accounting Policies: Stock-based Compensation (Policies) link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - 7. Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - 2. Summary of Significant Accounting Policies: Use of Estimates (Policies) link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - Viatar CTC Solutions, Inc. - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 000420 - Disclosure - 2. Summary of Significant Accounting Policies: Earnings (loss) Per Share: Schedule of Common Stock Equivalents Text Block (Details) link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - Viatar CTC Solutions, Inc. - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - 3. Property and Equipment link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - 2. Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies) link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - 9. Stockholders' Equity (deficit) link:presentationLink link:definitionLink link:calculationLink 000440 - Disclosure - 4. Investment in Non-publicly Traded Company (Details) link:presentationLink link:definitionLink link:calculationLink 000260 - Disclosure - 2. Summary of Significant Accounting Policies: Derivatives (Policies) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - 5. Convertible Notes Payable link:presentationLink link:definitionLink link:calculationLink 000400 - Disclosure - 1. Nature of Operations (Details) link:presentationLink link:definitionLink link:calculationLink 000300 - Disclosure - 2. Summary of Significant Accounting Policies: Earnings (loss) Per Share (Policies) link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - 2. Summary of Significant Accounting Policies: Cost-method Investment (Policies) link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - 2. Summary of Significant Accounting Policies: Cash (Policies) link:presentationLink link:definitionLink link:calculationLink 000430 - Disclosure - 3. Property and Equipment: Property, Plant and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - 6. Fair Value of Financial Instruments link:presentationLink link:definitionLink link:calculationLink 000480 - Disclosure - 8. Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 000490 - Disclosure - 9. Stockholders' Equity (deficit) (Details) link:presentationLink link:definitionLink link:calculationLink 000380 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Stockholders' Equity Note, Warrants or Rights (Tables) link:presentationLink link:definitionLink link:calculationLink 000340 - Disclosure - 3. Property and Equipment: Property, Plant and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 4 vrtt-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 5 vrtt-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 vrtt-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Debt Instrument, Unamortized Discount Non-Publicly Traded Company [Axis] Proceeds from Issuance or Sale of Equity Property and Equipment Notes Net loss attributable to stockholders before preferred dividends Represents the monetary amount of Net loss attributable to stockholders before preferred dividends, during the indicated time period. EXPENSES GROSS MARGIN GROSS MARGIN Preferred Stock Entity Public Float Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Related Party Transactions [Axis] Schedule of Assumptions Used Schedule of Investment in Non Publicly Traded Company Text Block Investment in Non Publicly Traded Company Text Block. Cash {1} Cash Proceeds from issuance of Preferred B shares, net of offering costs Proceeds from promissory note from common stock subscription. Cash flows from financing activities: Preferred Stock, Shares Outstanding Convertible notes payable - net of long term Document Fiscal Period Focus Warrants Exercisable Warrants Exercisable Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Recent Accounting Pronouncements Fair Value of Financial Instruments Cash, beginning of period Cash, beginning of period Cash, end of period COST OF REVENUE Accumulated deficit Total Liabilities Total Liabilities Accounts payable and accrued expenses Entity Voluntary Filers Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Accumulated Deficit Accumulated Deficit Accumulated Deficit. Commitments and Contingencies {1} Commitments and Contingencies 8. Related Party Transactions 2. Summary of Significant Accounting Policies Purchase of equipment Depreciation expense Weighted average shares Common stock Current Assets: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Equity Financing Equity Financing. Notes, Loans and Financing Receivable, Net, Current Operating Leases, Rent Expense Schedule of Non Vested Restricted Stock Text Block Schedule of Non Vested Restricted Stock Text Block. Research and Development 10. Subsequent Events 1. Nature of Operations Dividends accrued on Series B Preferred Dividends paid with Series B Preferred shares. Discount on debt issued with warrants Supplemental disclosure of non-cash financing activities: Net cash provided by investing activities LOSS PER COMMON SHARE BASIC AND DILUTED: Income Statement ASSETS Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Non-Publicly Traded Company Common Stock Warrants Common Stock Warrants. Revenue Recognition Repayment of demand notes Proceeds from sale of investment in non-publicly traded company. Proceeds from demand note Cash flows from investing activities: Less: Preferred dividends Net loss attributable to stockholders before preferred dividends. Income tax expense Dividend income TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Stockholders' Equity (Deficit): Prepaid expenses Cash Entity Registrant Name Related Party Transactions Short-term Debt, Type Total Common Stock Equivalents Total Common Stock Equivalents. 3. Property and Equipment Dividends paid with Series B Preferred shares Proceeds from issuance of Preferred B shares, net of offering costs. OTHER INCOME (EXPENSE) Current Fiscal Year End Date Amendment Description Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Operating Leases, Rent Expense, Contingent Rentals Investments Schedule of Common Stock Equivalents Text Block Schedule of Common Stock Equivalents Text Block. Accrued expenses Changes in operating assets and liabilities: Amortization of discount on debt Net loss attributable to stockholders Represents the monetary amount of Net loss attributable to stockholders, during the indicated time period. Common Stock, Shares Outstanding Series B Preferred Stock Represents the monetary amount of Series B Preferred Stock, as of the indicated date. Entity Current Reporting Status Statement [Line Items] Convertible Note Issued Convertible Note Issued. Conversion Feature on Series B Preferred Stock Conversion Feature on Series B Preferred Stock. Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Tables/Schedules Derivatives 6. Fair Value of Financial Instruments Proceeds from promissory note from common stock subscription Proceeds from convertible note payable. Cash flows from operating activities: Noncontrolling interest Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Series A Preferred Stock Shares Series A Preferred Stock Shares. Equity Method Investment, Ownership Percentage Related Party Transactions 2015 Machinery and Equipment, Gross Limited Liability Company or Limited Partnership, Business, Formation Date Schedule of Warrant Activity Text Block Schedule of Warrant Activity Text Block. Preferred Stock, Shares Issued Total Current Liabilities Total Current Liabilities Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Debt Conversion, Converted Instrument, Shares Issued Activity for the Investments in Non-Publicly Traded Company, Balance Investments and Other Noncurrent Assets Conversion Feature on Convertible Notes Conversion Feature on Convertible Notes. Cost of Sales Principles of Consolidation 5. Convertible Notes Payable 4. Investment in Non-publicly Traded Company Investment in Non Publicly Traded Company Text Block. Supplemental disclosures of cash flow information: Proceeds from convertible note payable Repayment of demand notes. Net cash used in operating activities Net cash used in operating activities Stock based compensation Net loss attributable to noncontrolling interest in consolidated subsidiary TOTAL OTHER INCOME (EXPENSE) General and administrative Sales TOTAL STOCKHOLDERS' EQUITY (DEFICIT) TOTAL STOCKHOLDERS' EQUITY (DEFICIT) Total current assets Total current assets Document Period End Date Document Type Entity Central Index Key Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Compensation Relative Fair Value of Warrants Issued Relative fair value of warrants issued. Related Party Transactions 2014 Operating Leases, Future Minimum Payments Due Class of Warrant or Right, Number of Securities Called by Warrants or Rights Additions Additions. Statement of Cash Flows Interest expense Common Stock, Par Value Preferred Stock, Shares Authorized Preferred Stock, Par Value Amendment Flag Unrecognized Tax Benefits, Interest on Income Taxes Expense Short-term Debt, Type [Axis] Property, Plant and Equipment Income Taxes Policies 7. Commitments and Contingencies Proceeds from sale of investment in non-publicly traded company Cash received for common stock receivable and interest. Research and development Cost of sales Represents the monetary amount of Cost of sales, during the indicated time period. Series A Preferred Stock Series B Preferred Stock. Property and equipment, net Statement of Financial Position Entity Filer Category Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Debt Instrument, Interest Rate, Stated Percentage Proceeds from Convertible Debt Convertible Notes Payable, fourth quarter Convertible Note Issued, Value Convertible Note Issued. Stock-based Compensation Basis of Accounting Net cash provided by financing activities Proceeds from issuance of stock and warrants Adjustments to reconcile net loss to net cash used in operating activities: Net loss attributable to common stockholders REVENUE Common Stock, Shares Issued Total Stockholders' equity (deficit) Document Fiscal Year Focus Entity Common Stock, Shares Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Class of Warrant or Right, Outstanding Series B Preferred Stock Shares Series B Preferred Stock Shares. Debt Instrument, Face Amount Statement [Table] Reclassification Cost-method Investment Use of Estimates Total expenses EX-101.PRE 7 vrtt-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-10.1 8 f101.htm EXHIBIT 10.1 Converted by EDGARwiz

AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT

This Amendment No. 1 to Executive Employment Agreement (this “Amendment”), dated as of October 21, 2016, is entered into by and among Viatar CTC Solutions Inc., a Delaware corporation (the “Company”), and Ilan Reich, an individual (the “Executive”).

WITNESSETH:

WHEREAS, the Company and the Executive are party to an executive employment agreement, dated on or about May 23, 2016 (the “Employment Agreement”);

WHEREAS, the Company and the Executive desire to amend the Employment Agreement as more particularly set forth below;

NOW, THEREFORE, in consideration of the covenants and mutual promises contained herein and other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged and intending to be legally bound hereby, the parties agree as follows:

The third and fourth sentences of Section 5 are hereby deleted in their entirety and replaced by the following which are hereby inserted in lieu thereof:

For purposes hereof, “Milestone Goal” shall mean (i) positive Earnings Before Interest Taxes Depreciation and Amortization, or EBITDA, for the Company’s last fiscal year, as reflected in the Company’s Annual Report on Form 10-K, and (ii) gross revenues of more than $20,000,000 for the Company’s last fiscal year, as reflected in the Company’s Annual Report on Form 10-K. The Bonus will be paid in stock, solely to the Executive, or, in the Executive’s sole discretion, fully or partially to employees and/or officers of the Company, in such amounts (up to the total amount of the Bonus) and to such employees and/or officers as designated by the Executive in writing to the Company.

Except as modified herein, the terms of the Employment Agreement shall remain in full force and effect.

This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and shall be binding upon all parties, their successors and assigns, and all of which taken together shall constitute one and the same Amendment. A signature delivered by facsimile shall constitute an original.

[Signature Page Follows]

[SIGNATURE PAGE TO AMENDMENT TO EMPLOYMENT AGREEMENT]

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date set forth above.

COMPANY

VIATAR CTC SOLUTIONS INC.

By: /s/ Ilan Reich

Name: Ilan Reich

Title: CEO

EXECUTIVE

/s/ Ilan Reich

Ilan Reich

EX-31.1 9 f311.htm EXHIBIT 31.1 Converted by EDGARwiz

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ilan Reich, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Viatar CTC Solutions Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and he audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: November 14, 2016




	/s/ Ilan Reich
	Ilan Reich Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)

EX-32.1 10 f321.htm EXHIBIT 32.1 Converted by EDGARwiz

Exhibit 32.1

CERTIFICATION

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Viatar CTC Solutions Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ilan Reich, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:




	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




Date: November 14, 2016
	/s/ Ilan Reich
	Ilan Reich
	Chief Executive Officer and Chief Financial Officer
	(Principal Executive Officer and Principal Financial Officer)

XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	9 Months Ended
Document And Entity Information	Sep. 30, 2016 shares
Document And Entity Information
Entity Registrant Name	Viatar CTC Solutions Inc.
Entity Central Index Key	0001616495
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Entity Filer Category	Smaller Reporting Company
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	19,495,426
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	vrtt

XML 12 R2.htm IDEA: XBRL DOCUMENT

Viatar CTC Solutions, Inc. - Condensed Consolidated Balance Sheets - USD ($)

Sep. 30, 2016

Dec. 31, 2015

Current Assets:

Cash

$ 630,260

$ 508,445

Prepaid expenses

19,679

247,659

Total current assets

649,939

756,104

Property and equipment, net

685,264

172,793

Investment in non-publicly traded company

480,000

Total Assets

1,335,203

1,408,897

Current liabilities:

Accounts payable and accrued expenses

385,548

368,116

Accrued income tax liability

626,887

Convertible notes payable - net of long term

100,000

Total Current Liabilities

1,112,435

995,003

Convertible note payable, net

2,070,481

2,126,218

Total Liabilities

3,182,916

3,121,221

Commitments and contingencies

Stockholders' Equity (Deficit):

Series A Preferred Stock

^[1]

4,000

Series B Preferred Stock

^[2]

1,734

Preferred Stock

^[3]

Common stock

19,496

^[4]

18,606

^[2]

Additional paid-in capital

26,959,694

20,492,974

Accumulated deficit

(28,822,215)

(22,217,527)

Total Stockholders' equity (deficit)

(1,837,291)

(1,701,947)

Noncontrolling interest

(10,422)

(10,377)

TOTAL STOCKHOLDERS' EQUITY (DEFICIT)

(1,847,713)

(1,712,324)

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

$ 1,335,203

$ 1,408,897

[1]	$0.001 par value, 4,000,000 shares authorized, 4,000,000 shares issued and oustanding at September 30, 2016 and December 31, 2015, respectively.
[2]	$0.001 par value, 5,000,000 shares authorized, 1,733,801 and 0 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively.
[3]	$0.001 par value, 11,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively.
[4]	$0.001 par value, 100,000,000 shares authorized; 19,495,426 and 18,605,426 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively.

XML 13 R3.htm IDEA: XBRL DOCUMENT

Statement of Financial Position - Parenthetical - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	11,000,000	11,000,000
Preferred Stock, Shares Issued
Preferred Stock, Shares Outstanding
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares Issued	19,495,426	18,605,426
Common Stock, Shares Outstanding	19,495,426	18,605,426

XML 14 R4.htm IDEA: XBRL DOCUMENT

Viatar CTC Solutions, Inc. - Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
REVENUE
Sales		$ 13,985		$ 37,940
COST OF REVENUE
Cost of sales		3,830		7,660
GROSS MARGIN		10,155		30,280
EXPENSES
Research and development	$ 921,577	677,878	$ 3,556,577	1,889,156
General and administrative	419,932	244,066	2,636,588	941,534
Total expenses	1,341,509	921,944	6,193,165	2,830,690
LOSS FROM OPERATIONS	(1,341,509)	(921,944)	(1,693,165)	(2,830,690)
OTHER INCOME (EXPENSE)
Dividend income			3,227
Interest expense	(52,261)	(16,413)	(168,994)	(73,132)
TOTAL OTHER INCOME (EXPENSE)	(1,393,770)	(928,202)	(6,358,932)	(2,873,542)
Income tax expense	(5,799)	(6,582)	(6,750)	(6,582)
Net loss	(1,399,569)	(934,784)	(6,365,682)	(2,880,124)
Net loss attributable to noncontrolling interest in consolidated subsidiary	(11)	(120)	(45)	(393)
Net loss attributable to stockholders before preferred dividends	(1,399,558)	(934,664)	(6,365,637)	(2,879,731)
Less: Preferred dividends	(103,790)		(239,051)
Net loss attributable to stockholders	$ (1,503,348)	$ (934,664)	$ (6,604,688)	$ (2,879,731)
LOSS PER COMMON SHARE BASIC AND DILUTED:
Net loss attributable to common stockholders	$ (0.08)	$ (0.05)	$ (0.34)	$ (0.16)
Weighted average shares	19,495,426	17,981,054	19,196,594	17,604,366

XML 15 R5.htm IDEA: XBRL DOCUMENT

Viatar CTC Solutions, Inc. - Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (6,365,682)	$ (2,880,124)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	2,362,823	1,117,015
Amortization of discount on debt	44,263	37,654
Depreciation expense	87,368
Changes in operating assets and liabilities:
Accrued expenses	(86,358)	(69,528)
Net cash used in operating activities	(3,957,586)	(1,794,983)
Cash flows from investing activities:
Proceeds from sale of investment in non-publicly traded company	480,000
Purchase of equipment	(599,839)
Net cash provided by investing activities	(119,839)
Cash flows from financing activities:
Proceeds from demand note		50,000
Repayment of demand notes		(100,000)
Proceeds from convertible note payable		300,000
Proceeds from promissory note from common stock subscription		611,939
Proceeds from issuance of stock and warrants		1,009,125
Proceeds from issuance of Preferred B shares, net of offering costs	4,199,240
Net cash provided by financing activities	4,199,240	1,871,064
Net increase in cash and cash equivalents	121,815	76,081
Cash, beginning of period	508,445	31,351
Cash, end of period	630,260	107,432
Supplemental disclosures of cash flow information:
Cash paid for interest	54,734	4,291
Supplemental disclosure of non-cash financing activities:
Discount on debt issued with warrants		$ 31,149
Dividends paid with Series B Preferred shares	135,261
Dividends accrued on Series B Preferred	$ 103,790

XML 16 R6.htm IDEA: XBRL DOCUMENT

1. Nature of Operations

9 Months Ended

Sep. 30, 2016

Notes

1. Nature of Operations

1. NATURE OF OPERATIONS

Viatar CTC Solutions and Vizio are together referred to as the “Company”.

Since inception, the Company has not generated significant revenues. As a result, we have incurred significant net losses and significant negative cash flows from operations.

The Company has raised approximately $21,700,000 of capital since its inception, including $20.3 million from the sale of common and Series B Preferred stock, $1.4 million from convertible notes and $100,000 of demand notes. Management is continually pursuing additional funding sources.

XML 17 R7.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2016

Notes

2. Summary of Significant Accounting Policies

Basis of Accounting

Principles of Consolidation

Use of Estimates

Cash

Fair Value of Financial Instruments

Property and Equipment

Property and equipment are recorded at cost. Depreciation expense is computed using straight-line methods over the estimated useful lives.

Asset lives for financial statement reporting of depreciation are:

Machinery and equipment

5 years

Cost-Method Investment

As of September 30, 2016 the Company does not have any investment in any non-publicly traded company. See Note 4.

Revenue Recognition

Cost of Sales

Research and Development

Research and development costs consist of ongoing testing (including pre-clinical and clinical), research and development, and are expensed as incurred.

Derivatives

Income Taxes

Commitments and Contingencies

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

Stock-Based Compensation

Earnings (Loss) Per Share

The Company had the following potential common stock equivalents as of September 30, 2016 and 2015:

As of	September 30, 2016	September 30, 2015
Common stock warrants, exercise price range of $1.00-$2.00	777,981	-
Conversion feature on convertible notes, exercise price of $2.50	920,000	120,000
Conversion feature on Series B preferred stock, exercise price of $2.50	1,733,801	535,000
Total common stock equivalents	3,431,782	655,000

Reclassification

Certain prior period amounts have been reclassified to conform to current period presentation. The reclassifications did not have an impact on net loss as previously reported.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying consolidated financial statements.

XML 18 R8.htm IDEA: XBRL DOCUMENT

3. Property and Equipment

9 Months Ended

Sep. 30, 2016

Notes

3. Property and Equipment

3. PROPERTY AND EQUIPMENT

Property and equipment on September 30, 2016 and December 31, 2015 are as follows:

	September 30, 2016		December 31, 2015
Machinery and Equipment	$	775,422	$	175,583

Less: Accumulated Depreciation		90,158		2,790
	$	685,264	$	172,793

XML 19 R9.htm IDEA: XBRL DOCUMENT

4. Investment in Non-publicly Traded Company

9 Months Ended

Sep. 30, 2016

Notes

4. Investment in Non-publicly Traded Company

4. INVESTMENT IN NON-PUBLICLY TRADED COMPANY

The following table summarizes the activity for the investment in non-publicly traded company:

	September 30, 2016
Balance at January 1, 2016	$	480,000
Additions – stock of non-publicly traded company		-
Disposal – sale of stock of non-publicly traded company		(480,000)
Balance at September 30, 2016	$	-

XML 20 R10.htm IDEA: XBRL DOCUMENT

5. Convertible Notes Payable

9 Months Ended

Sep. 30, 2016

Notes

5. Convertible Notes Payable

5. CONVERTIBLE NOTES PAYABLE

During the third and fourth quarters of 2015, the Company borrowed an aggregate of $1,300,000 in exchange for 4% convertible notes (the “4% Convertible Notes”) with the following terms: (i) maturing on October 1, 2018 ($300,000) and November 1, 2018 ($1,000,000) (ii) quarterly cash interest due of 4% (iii) convertible into common stock at any time at the holder’s option at $2.50 per share and (iv) automatically convertible into common stock after May 5, 2017 at $2.50 per share if after that date the common stock trades above that price for 20 trading days with an average daily volume of 25,000 shares. As discussed in Note 8, $1.0 million was borrowed from a related party.

XML 21 R11.htm IDEA: XBRL DOCUMENT

6. Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2016

Notes

6. Fair Value of Financial Instruments

6. FAIR VALUE OF FINANCIAL INSTRUMENTS

XML 22 R12.htm IDEA: XBRL DOCUMENT

7. Commitments and Contingencies

9 Months Ended

Sep. 30, 2016

Notes

7. Commitments and Contingencies

7. COMMITMENTS AND CONTINGENCIES

Operating Lease

Employment Agreement

XML 23 R13.htm IDEA: XBRL DOCUMENT

8. Related Party Transactions

9 Months Ended

Sep. 30, 2016

Notes

8. Related Party Transactions

8. RELATED PARTY TRANSACTIONS

In December 2014, the Company borrowed an aggregate of $50,000 in exchange for an interest free demand note from a former member of the board of managers. The loan was repaid in January 2015.

In October 2015, the Company sold a 4% Convertible Note in the principal amount of $1,000,000 to a related party. See Note 5.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity (deficit)

9 Months Ended

Sep. 30, 2016

Notes

9. Stockholders' Equity (deficit)

9. Stockholders’ EQUITY (deficit)

During January 2015, the Company received $611,939 for the payoff of notes originally issued to purchase common stock and all accrued interest.

In January 2015, the Company entered into an equity financing agreement with a third party who committed to raise an aggregate of $1,500,000 by February 28, 2016. This commitment was satisfied through (a) the sale of an aggregate of 697,000 shares of common stock to accredited investors for proceeds of $1,009,125 (for an average price of $1.45 per share) net of offering costs of $134,750, and (b) the exchange of 4% Convertible Notes for stock of a non-publicly traded company (See Note 4).

· have a stated value of $2.50 and a conversion price of $2.50, subject to certain adjustments;

· are convertible into such number of shares of common stock as determined by dividing the number of shares of Series B Preferred Stock being converted, multiplied by the stated value, divided by the conversion price then in effect;

· are entitled to one vote for each share of Series B Preferred Stock on any matter submitted to holders of common stock;

· are entitled to dividends at the annual rate of 9.5% (which will increase to 12% in the event that by June 30, 2018, the Company does not obtain CE Mark approval of its Therapeutic Oncopheresis System and generate at least $600,000 of gross profit in two fiscal quarters, subject to certain conditions), payable quarterly in shares of Series B Preferred Stock;

· upon any liquidation, will be entitled to receive, prior to any payments in respect of the Company’s common stock, an amount equal to the stated value plus any accrued but unpaid dividends; and

· beginning in 2022, will automatically convert into common stock in the event that the closing price of the common stock is at least $4.00 for 20 consecutive trading days with a minimum average trading volume of at least 25,000 shares for such period.

As of September 30, 2016, 4,000,000 shares of Series A Preferred Stock, 1,733,801 shares of Series B Preferred Stock and 19,495,426 shares of common stock were issued and outstanding.

See Note 2 for a description of potential common stock equivalents.

Restricted Stock

	Restricted Stock		Weighted Average Exercise Price

Non-vested – December 31, 2015		470,167	$	1.72
Granted		960,000	$	1.68
Vested		(1,064,333)	$	1.69
Forfeited/Cancelled		-	$	-
Non-vested – September 30, 2016		365,834	$	1.70

The following is a summary of the Company’s warrant activity:

	Warrants		Weighted Average Exercise Price

Outstanding – January 1, 2016		535,000	$	1.42
Exercisable –January 1, 2016		535,000	$	1.42
Granted		417,981	$	1.50
Exercised		-	$	-
Forfeited/Cancelled		(175,000)	$	-
Outstanding – September 30, 2016		777,981	$	1.42
Exercisable – September 30, 2016		777,981	$	1.42

Warrants Outstanding						Warrants Exercisable
Range of Exercise Price	Number Outstanding		Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$1.00-$2.00		777,981	3.67 years	$	1.42	777,981	$	1.42

Assumptions		September 30, 2016

Expected term (years)		5.00
Expected volatility		86.6%
Risk-free interest rate		1.24%
Dividend yield		0.00%

During the nine months ended September 30, 2016, the Company issued warrants for advisory services and expensed an aggregate of $348,911 as stock based compensation.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

10. Subsequent Events

9 Months Ended

Sep. 30, 2016

Notes

10. Subsequent Events

10. SUBSEQUENT EVENTS

In October 2016, the Company borrowed $300,000 from the President and CEO of the Company pursuant to an interest-free demand note.

XML 26 R16.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Basis of Accounting (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Basis of Accounting

XML 27 R17.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Principles of Consolidation (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Principles of Consolidation

XML 28 R18.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Use of Estimates (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Use of Estimates

XML 29 R19.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Cash (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Cash

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References + Details

XML 30 R20.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Fair Value of Financial Instruments

XML 31 R21.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Property and Equipment (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Property and Equipment

Property and equipment are recorded at cost. Depreciation expense is computed using straight-line methods over the estimated useful lives.

Asset lives for financial statement reporting of depreciation are:

Machinery and equipment

5 years

XML 32 R22.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Cost-method Investment (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Cost-method Investment

Cost-Method Investment

As of September 30, 2016 the Company does not have any investment in any non-publicly traded company. See Note 4.

XML 33 R23.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Revenue Recognition (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Revenue Recognition

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

XML 34 R24.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Cost of Sales (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Cost of Sales

XML 35 R25.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Research and Development (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Research and Development

Research and development costs consist of ongoing testing (including pre-clinical and clinical), research and development, and are expensed as incurred.

XML 36 R26.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Derivatives (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Derivatives

XML 37 R27.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Income Taxes (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Income Taxes

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

XML 38 R28.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Commitments and Contingencies (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Commitments and Contingencies

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

XML 39 R29.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Stock-based Compensation (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Stock-based Compensation

Stock-Based Compensation

XML 40 R30.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Earnings (loss) Per Share (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Earnings (loss) Per Share

Earnings (Loss) Per Share

The Company had the following potential common stock equivalents as of September 30, 2016 and 2015:

As of	September 30, 2016	September 30, 2015
Common stock warrants, exercise price range of $1.00-$2.00	777,981	-
Conversion feature on convertible notes, exercise price of $2.50	920,000	120,000
Conversion feature on Series B preferred stock, exercise price of $2.50	1,733,801	535,000
Total common stock equivalents	3,431,782	655,000

XML 41 R31.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Reclassification (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Reclassification

Certain prior period amounts have been reclassified to conform to current period presentation. The reclassifications did not have an impact on net loss as previously reported.

XML 42 R32.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)

9 Months Ended

Sep. 30, 2016

Policies

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying consolidated financial statements.

XML 43 R33.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Earnings (loss) Per Share: Schedule of Common Stock Equivalents Text Block (Tables)

9 Months Ended

Sep. 30, 2016

Tables/Schedules

Schedule of Common Stock Equivalents Text Block

As of	September 30, 2016	September 30, 2015
Common stock warrants, exercise price range of $1.00-$2.00	777,981	-
Conversion feature on convertible notes, exercise price of $2.50	920,000	120,000
Conversion feature on Series B preferred stock, exercise price of $2.50	1,733,801	535,000
Total common stock equivalents	3,431,782	655,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

3. Property and Equipment: Property, Plant and Equipment (Tables)

9 Months Ended

Sep. 30, 2016

Tables/Schedules

Property, Plant and Equipment

	September 30, 2016		December 31, 2015
Machinery and Equipment	$	775,422	$	175,583

Less: Accumulated Depreciation		90,158		2,790
	$	685,264	$	172,793

XML 45 R35.htm IDEA: XBRL DOCUMENT

4. Investment in Non-publicly Traded Company: Schedule of Investment in Non Publicly Traded Company Text Block (Tables)

9 Months Ended

Sep. 30, 2016

Tables/Schedules

Schedule of Investment in Non Publicly Traded Company Text Block

	September 30, 2016
Balance at January 1, 2016	$	480,000
Additions – stock of non-publicly traded company		-
Disposal – sale of stock of non-publicly traded company		(480,000)
Balance at September 30, 2016	$	-

XML 46 R36.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity (deficit): Schedule of Non Vested Restricted Stock Text Block (Tables)

9 Months Ended

Sep. 30, 2016

Tables/Schedules

Schedule of Non Vested Restricted Stock Text Block

	Restricted Stock		Weighted Average Exercise Price

Non-vested – December 31, 2015		470,167	$	1.72
Granted		960,000	$	1.68
Vested		(1,064,333)	$	1.69
Forfeited/Cancelled		-	$	-
Non-vested – September 30, 2016		365,834	$	1.70

XML 47 R37.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity (deficit): Schedule of Warrant Activity Text Block (Tables)

9 Months Ended

Sep. 30, 2016

Tables/Schedules

Schedule of Warrant Activity Text Block

	Warrants		Weighted Average Exercise Price

Outstanding – January 1, 2016		535,000	$	1.42
Exercisable –January 1, 2016		535,000	$	1.42
Granted		417,981	$	1.50
Exercised		-	$	-
Forfeited/Cancelled		(175,000)	$	-
Outstanding – September 30, 2016		777,981	$	1.42
Exercisable – September 30, 2016		777,981	$	1.42

XML 48 R38.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity (deficit): Schedule of Stockholders' Equity Note, Warrants or Rights (Tables)

9 Months Ended

Sep. 30, 2016

Tables/Schedules

Schedule of Stockholders' Equity Note, Warrants or Rights

Warrants Outstanding						Warrants Exercisable
Range of Exercise Price	Number Outstanding		Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$1.00-$2.00		777,981	3.67 years	$	1.42	777,981	$	1.42

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 49 R39.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity (deficit): Schedule of Assumptions Used (Tables)

9 Months Ended

Sep. 30, 2016

Tables/Schedules

Schedule of Assumptions Used

Assumptions		September 30, 2016

Expected term (years)		5.00
Expected volatility		86.6%
Risk-free interest rate		1.24%
Dividend yield		0.00%

XML 50 R40.htm IDEA: XBRL DOCUMENT

1. Nature of Operations (Details) - USD ($)	3 Months Ended	9 Months Ended
1. Nature of Operations (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015
Details
Limited Liability Company or Limited Partnership, Business, Formation Date	Dec. 18, 2007
Net Income (Loss) Attributable to Parent		$ 6,365,682
Net cash used in operating activities		3,957,586	$ 1,794,983
Working Capital Deficit	$ 462,496	462,496
Accumulated Deficit	$ 28,822,215	28,822,215
Proceeds from Issuance or Sale of Equity		$ 21,700,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 51 R41.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Principles of Consolidation (Details)	Sep. 30, 2016
Details
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	0.00%

XML 52 R42.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies: Earnings (loss) Per Share: Schedule of Common Stock Equivalents Text Block (Details) - shares	Sep. 30, 2016	Sep. 30, 2015
Details
Common Stock Warrants	777,981
Conversion Feature on Convertible Notes	920,000	120,000
Conversion Feature on Series B Preferred Stock	1,733,801	535,000
Total Common Stock Equivalents	3,431,782	655,000

XML 53 R43.htm IDEA: XBRL DOCUMENT

3. Property and Equipment: Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Details
Machinery and Equipment, Gross	$ 775,422	$ 175,583
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 90,158	$ 2,790

XML 54 R44.htm IDEA: XBRL DOCUMENT

4. Investment in Non-publicly Traded Company (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2016
Details
Convertible Note Issued	60,000
Convertible Note Issued, Value	$ 720,000
Investments and Other Noncurrent Assets		$ 0

XML 55 R45.htm IDEA: XBRL DOCUMENT

4. Investment in Non-publicly Traded Company: Schedule of Investment in Non Publicly Traded Company Text Block (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Jan. 02, 2016
Disposal	$ (480,000)
Activity for the Investments in Non-Publicly Traded Company, Balance
Investments		$ 480,000

XML 56 R46.htm IDEA: XBRL DOCUMENT

5. Convertible Notes Payable (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
5. Convertible Notes Payable (Details) - USD ($)	Apr. 30, 2013	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2015	Sep. 30, 2016
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	50,000
Discount on debt issued with warrants	$ 32,525		$ 31,149
Debt Instrument, Unamortized Discount				$ 0	$ 0
Convertible Notes Payable
Proceeds from Convertible Debt	$ 100,000
Debt Instrument, Interest Rate, Stated Percentage	4.00%
Convertible Notes Payable, third quarter
Proceeds from Convertible Debt		$ 1,300,000
Debt Instrument, Interest Rate, Stated Percentage		4.00%	4.00%	4.00%
Convertible Notes Payable, fourth quarter
Proceeds from Convertible Debt				$ 900,000
Debt Instrument, Unamortized Discount				$ 173,782	$ 129,519

XML 57 R47.htm IDEA: XBRL DOCUMENT

7. Commitments and Contingencies (Details) - USD ($)	1 Months Ended	12 Months Ended
7. Commitments and Contingencies (Details) - USD ($)	Jun. 30, 2012	Dec. 31, 2015	Mar. 31, 2015
Details
Operating Leases, Rent Expense, Contingent Rentals	$ 3,103
Operating Leases, Future Minimum Payments Due			$ 9,309
Operating Leases, Rent Expense		$ 91,050

- Definition

The increases or decreases in lease payments that result from changes occurring after the inception of the lease in the factors (other than the passage of time) on which lease payments are based, except that any escalation of minimum lease payments relating to increases in construction or acquisition cost of the leased property or for increases in some measure of cost or value during the construction or preconstruction period, are excluded from contingent rentals. Contingent rentals also may include amounts for which the triggering events have not yet occurred or the specified targets for which have not yet been achieved (such as sales based percentage rent), but which events are considered probable of occurring or which specified targets are considered probable of being achieved.

+ References + Details

XML 58 R48.htm IDEA: XBRL DOCUMENT

8. Related Party Transactions (Details) - USD ($)	1 Months Ended	9 Months Ended
8. Related Party Transactions (Details) - USD ($)	Jan. 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Common Stock, Par Value		$ 0.001		$ 0.001
Amortization of discount on debt		$ 44,263	$ 37,654
Related Party Transactions 2014
Debt Instrument, Face Amount					$ 50,000
Related Party Transactions 2015
Debt Instrument, Face Amount	$ 50,000
Debt Conversion, Converted Instrument, Shares Issued	50,000
Common Stock, Par Value	$ 1.00
Relative Fair Value of Warrants Issued	$ 31,149
Amortization of discount on debt	$ 31,149

XML 59 R49.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity (deficit) (Details) - USD ($)	1 Months Ended	9 Months Ended
9. Stockholders' Equity (deficit) (Details) - USD ($)	Jan. 31, 2015	Sep. 30, 2016	Dec. 31, 2015
Details
Common Stock, Shares Authorized		100,000,000	100,000,000
Preferred Stock Authorized		20,000,000
Equity Method Investment, Ownership Percentage		20.00%
Notes, Loans and Financing Receivable, Net, Current	$ 611,939
Equity Financing	$ 1,500,000
Series A Preferred Stock Shares		4,000,000
Series B Preferred Stock Shares		1,733,801
Common Stock, Shares Outstanding		19,495,426	18,605,426
Compensation		$ 1,888,287
Unrecognized Tax Benefits, Interest on Income Taxes Expense		$ 186,898

XML 60 R50.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity (deficit): Schedule of Non Vested Restricted Stock Text Block (Details) - $ / shares	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Details
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	365,834	470,167
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 1.70	$ 1.72
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	960,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value	$ 1.68
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	(1,064,333)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value	$ 1.69

XML 61 R51.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity (deficit): Schedule of Warrant Activity Text Block (Details) - $ / shares	9 Months Ended
	Sep. 30, 2016	Jan. 02, 2016
Details
Class of Warrant or Right, Outstanding	777,981	535,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 1.42	$ 1.42
Warrants Exercisable	777,981	535,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 1.42	$ 1.42
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	417,981
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	(175,000)

XML 62 R52.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity (deficit): Schedule of Stockholders' Equity Note, Warrants or Rights (Details) - $ / shares	9 Months Ended
	Sep. 30, 2016	Jan. 02, 2016
Details
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 1.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 2.00
Class of Warrant or Right, Outstanding	777,981	535,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	3 years 8 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 1.42	$ 1.42
Warrants Exercisable	777,981	535,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 1.42	$ 1.42

XML 63 R53.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity (deficit): Schedule of Assumptions Used (Details)	9 Months Ended
	Sep. 30, 2016
Details
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	86.60%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.24%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%

EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 65 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 29 173 1 true 6 0 false 4 false false R1.htm 000010 - Document - Document And Entity Information Sheet http://viatarctcsolutioninc.com/20160930/role/idr_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 000020 - Statement - Viatar CTC Solutions, Inc. - Condensed Consolidated Balance Sheets Sheet http://viatarctcsolutioninc.com/20160930/role/idr_ViatarCTCSolutionsIncCondensedConsolidatedBalanceSheets Viatar CTC Solutions, Inc. - Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 000030 - Statement - Statement of Financial Position - Parenthetical Sheet http://viatarctcsolutioninc.com/20160930/role/idr_StatementOfFinancialPositionParenthetical Statement of Financial Position - Parenthetical Statements 3 false false R4.htm 000040 - Statement - Viatar CTC Solutions, Inc. - Condensed Consolidated Statements of Operations Sheet http://viatarctcsolutioninc.com/20160930/role/idr_ViatarCTCSolutionsIncCondensedConsolidatedStatementsOfOperations Viatar CTC Solutions, Inc. - Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 000050 - Statement - Viatar CTC Solutions, Inc. - Condensed Consolidated Statements of Cash Flows Sheet http://viatarctcsolutioninc.com/20160930/role/idr_ViatarCTCSolutionsIncCondensedConsolidatedStatementsOfCashFlows Viatar CTC Solutions, Inc. - Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 000060 - Disclosure - 1. Nature of Operations Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure1NatureOfOperations 1. Nature of Operations Notes 6 false false R7.htm 000070 - Disclosure - 2. Summary of Significant Accounting Policies Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 2. Summary of Significant Accounting Policies Notes 7 false false R8.htm 000080 - Disclosure - 3. Property and Equipment Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure3PropertyAndEquipment 3. Property and Equipment Notes 8 false false R9.htm 000090 - Disclosure - 4. Investment in Non-publicly Traded Company Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure4InvestmentInNonPubliclyTradedCompany 4. Investment in Non-publicly Traded Company Notes 9 false false R10.htm 000100 - Disclosure - 5. Convertible Notes Payable Notes http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure5ConvertibleNotesPayable 5. Convertible Notes Payable Notes 10 false false R11.htm 000110 - Disclosure - 6. Fair Value of Financial Instruments Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure6FairValueOfFinancialInstruments 6. Fair Value of Financial Instruments Notes 11 false false R12.htm 000120 - Disclosure - 7. Commitments and Contingencies Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure7CommitmentsAndContingencies 7. Commitments and Contingencies Notes 12 false false R13.htm 000130 - Disclosure - 8. Related Party Transactions Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure8RelatedPartyTransactions 8. Related Party Transactions Notes 13 false false R14.htm 000140 - Disclosure - 9. Stockholders' Equity (deficit) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficit 9. Stockholders' Equity (deficit) Notes 14 false false R15.htm 000150 - Disclosure - 10. Subsequent Events Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure10SubsequentEvents 10. Subsequent Events Notes 15 false false R16.htm 000160 - Disclosure - 2. Summary of Significant Accounting Policies: Basis of Accounting (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesBasisOfAccountingPolicies 2. Summary of Significant Accounting Policies: Basis of Accounting (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 16 false false R17.htm 000170 - Disclosure - 2. Summary of Significant Accounting Policies: Principles of Consolidation (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesPrinciplesOfConsolidationPolicies 2. Summary of Significant Accounting Policies: Principles of Consolidation (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 17 false false R18.htm 000180 - Disclosure - 2. Summary of Significant Accounting Policies: Use of Estimates (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesUseOfEstimatesPolicies 2. Summary of Significant Accounting Policies: Use of Estimates (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 18 false false R19.htm 000190 - Disclosure - 2. Summary of Significant Accounting Policies: Cash (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesCashPolicies 2. Summary of Significant Accounting Policies: Cash (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 19 false false R20.htm 000200 - Disclosure - 2. Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsPolicies 2. Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 20 false false R21.htm 000210 - Disclosure - 2. Summary of Significant Accounting Policies: Property and Equipment (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentPolicies 2. Summary of Significant Accounting Policies: Property and Equipment (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 21 false false R22.htm 000220 - Disclosure - 2. Summary of Significant Accounting Policies: Cost-method Investment (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesCostMethodInvestmentPolicies 2. Summary of Significant Accounting Policies: Cost-method Investment (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 22 false false R23.htm 000230 - Disclosure - 2. Summary of Significant Accounting Policies: Revenue Recognition (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesRevenueRecognitionPolicies 2. Summary of Significant Accounting Policies: Revenue Recognition (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 23 false false R24.htm 000240 - Disclosure - 2. Summary of Significant Accounting Policies: Cost of Sales (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesCostOfSalesPolicies 2. Summary of Significant Accounting Policies: Cost of Sales (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 24 false false R25.htm 000250 - Disclosure - 2. Summary of Significant Accounting Policies: Research and Development (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentPolicies 2. Summary of Significant Accounting Policies: Research and Development (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 25 false false R26.htm 000260 - Disclosure - 2. Summary of Significant Accounting Policies: Derivatives (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesDerivativesPolicies 2. Summary of Significant Accounting Policies: Derivatives (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 26 false false R27.htm 000270 - Disclosure - 2. Summary of Significant Accounting Policies: Income Taxes (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesIncomeTaxesPolicies 2. Summary of Significant Accounting Policies: Income Taxes (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 27 false false R28.htm 000280 - Disclosure - 2. Summary of Significant Accounting Policies: Commitments and Contingencies (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesCommitmentsAndContingenciesPolicies 2. Summary of Significant Accounting Policies: Commitments and Contingencies (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 28 false false R29.htm 000290 - Disclosure - 2. Summary of Significant Accounting Policies: Stock-based Compensation (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesStockBasedCompensationPolicies 2. Summary of Significant Accounting Policies: Stock-based Compensation (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 29 false false R30.htm 000300 - Disclosure - 2. Summary of Significant Accounting Policies: Earnings (loss) Per Share (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesEarningsLossPerSharePolicies 2. Summary of Significant Accounting Policies: Earnings (loss) Per Share (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 30 false false R31.htm 000310 - Disclosure - 2. Summary of Significant Accounting Policies: Reclassification (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesReclassificationPolicies 2. Summary of Significant Accounting Policies: Reclassification (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 31 false false R32.htm 000320 - Disclosure - 2. Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsPolicies 2. Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies) Policies http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 32 false false R33.htm 000330 - Disclosure - 2. Summary of Significant Accounting Policies: Earnings (loss) Per Share: Schedule of Common Stock Equivalents Text Block (Tables) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesEarningsLossPerShareScheduleOfCommonStockEquivalentsTextBlockTables 2. Summary of Significant Accounting Policies: Earnings (loss) Per Share: Schedule of Common Stock Equivalents Text Block (Tables) Tables http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPolicies 33 false false R34.htm 000340 - Disclosure - 3. Property and Equipment: Property, Plant and Equipment (Tables) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure3PropertyAndEquipmentPropertyPlantAndEquipmentTables 3. Property and Equipment: Property, Plant and Equipment (Tables) Tables 34 false false R35.htm 000350 - Disclosure - 4. Investment in Non-publicly Traded Company: Schedule of Investment in Non Publicly Traded Company Text Block (Tables) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure4InvestmentInNonPubliclyTradedCompanyScheduleOfInvestmentInNonPubliclyTradedCompanyTextBlockTables 4. Investment in Non-publicly Traded Company: Schedule of Investment in Non Publicly Traded Company Text Block (Tables) Tables 35 false false R36.htm 000360 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Non Vested Restricted Stock Text Block (Tables) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitScheduleOfNonVestedRestrictedStockTextBlockTables 9. Stockholders' Equity (deficit): Schedule of Non Vested Restricted Stock Text Block (Tables) Tables http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficit 36 false false R37.htm 000370 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Warrant Activity Text Block (Tables) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitScheduleOfWarrantActivityTextBlockTables 9. Stockholders' Equity (deficit): Schedule of Warrant Activity Text Block (Tables) Tables http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficit 37 false false R38.htm 000380 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Stockholders' Equity Note, Warrants or Rights (Tables) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitScheduleOfStockholdersEquityNoteWarrantsOrRightsTables 9. Stockholders' Equity (deficit): Schedule of Stockholders' Equity Note, Warrants or Rights (Tables) Tables http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficit 38 false false R39.htm 000390 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Assumptions Used (Tables) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitScheduleOfAssumptionsUsedTables 9. Stockholders' Equity (deficit): Schedule of Assumptions Used (Tables) Tables http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficit 39 false false R40.htm 000400 - Disclosure - 1. Nature of Operations (Details) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure1NatureOfOperationsDetails 1. Nature of Operations (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure1NatureOfOperations 40 false false R41.htm 000410 - Disclosure - 2. Summary of Significant Accounting Policies: Principles of Consolidation (Details) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesPrinciplesOfConsolidationDetails 2. Summary of Significant Accounting Policies: Principles of Consolidation (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesPrinciplesOfConsolidationPolicies 41 false false R42.htm 000420 - Disclosure - 2. Summary of Significant Accounting Policies: Earnings (loss) Per Share: Schedule of Common Stock Equivalents Text Block (Details) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesEarningsLossPerShareScheduleOfCommonStockEquivalentsTextBlockDetails 2. Summary of Significant Accounting Policies: Earnings (loss) Per Share: Schedule of Common Stock Equivalents Text Block (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure2SummaryOfSignificantAccountingPoliciesEarningsLossPerShareScheduleOfCommonStockEquivalentsTextBlockTables 42 false false R43.htm 000430 - Disclosure - 3. Property and Equipment: Property, Plant and Equipment (Details) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure3PropertyAndEquipmentPropertyPlantAndEquipmentDetails 3. Property and Equipment: Property, Plant and Equipment (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure3PropertyAndEquipmentPropertyPlantAndEquipmentTables 43 false false R44.htm 000440 - Disclosure - 4. Investment in Non-publicly Traded Company (Details) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure4InvestmentInNonPubliclyTradedCompanyDetails 4. Investment in Non-publicly Traded Company (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure4InvestmentInNonPubliclyTradedCompanyScheduleOfInvestmentInNonPubliclyTradedCompanyTextBlockTables 44 false false R45.htm 000450 - Disclosure - 4. Investment in Non-publicly Traded Company: Schedule of Investment in Non Publicly Traded Company Text Block (Details) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure4InvestmentInNonPubliclyTradedCompanyScheduleOfInvestmentInNonPubliclyTradedCompanyTextBlockDetails 4. Investment in Non-publicly Traded Company: Schedule of Investment in Non Publicly Traded Company Text Block (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure4InvestmentInNonPubliclyTradedCompanyScheduleOfInvestmentInNonPubliclyTradedCompanyTextBlockTables 45 false false R46.htm 000460 - Disclosure - 5. Convertible Notes Payable (Details) Notes http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure5ConvertibleNotesPayableDetails 5. Convertible Notes Payable (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure5ConvertibleNotesPayable 46 false false R47.htm 000470 - Disclosure - 7. Commitments and Contingencies (Details) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure7CommitmentsAndContingenciesDetails 7. Commitments and Contingencies (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure7CommitmentsAndContingencies 47 false false R48.htm 000480 - Disclosure - 8. Related Party Transactions (Details) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure8RelatedPartyTransactionsDetails 8. Related Party Transactions (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure8RelatedPartyTransactions 48 false false R49.htm 000490 - Disclosure - 9. Stockholders' Equity (deficit) (Details) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitDetails 9. Stockholders' Equity (deficit) (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitScheduleOfNonVestedRestrictedStockTextBlockTables 49 false false R50.htm 000500 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Non Vested Restricted Stock Text Block (Details) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitScheduleOfNonVestedRestrictedStockTextBlockDetails 9. Stockholders' Equity (deficit): Schedule of Non Vested Restricted Stock Text Block (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitScheduleOfNonVestedRestrictedStockTextBlockTables 50 false false R51.htm 000510 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Warrant Activity Text Block (Details) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitScheduleOfWarrantActivityTextBlockDetails 9. Stockholders' Equity (deficit): Schedule of Warrant Activity Text Block (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitScheduleOfNonVestedRestrictedStockTextBlockTables 51 false false R52.htm 000520 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Stockholders' Equity Note, Warrants or Rights (Details) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails 9. Stockholders' Equity (deficit): Schedule of Stockholders' Equity Note, Warrants or Rights (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitScheduleOfNonVestedRestrictedStockTextBlockTables 52 false false R53.htm 000530 - Disclosure - 9. Stockholders' Equity (deficit): Schedule of Assumptions Used (Details) Sheet http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitScheduleOfAssumptionsUsedDetails 9. Stockholders' Equity (deficit): Schedule of Assumptions Used (Details) Details http://viatarctcsolutioninc.com/20160930/role/idr_Disclosure9StockholdersEquityDeficitScheduleOfNonVestedRestrictedStockTextBlockTables 53 false false All Reports Book All Reports vrtt-20160930.xml vrtt-20160930.xsd vrtt-20160930_cal.xml vrtt-20160930_def.xml vrtt-20160930_lab.xml vrtt-20160930_pre.xml true true ZIP 70 0001511164-16-001136-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001511164-16-001136-xbrl.zip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ΰ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�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